WO1998006438A9 - Composition destinee a des applications pharmaceutiques - Google Patents
Composition destinee a des applications pharmaceutiquesInfo
- Publication number
- WO1998006438A9 WO1998006438A9 PCT/US1997/013988 US9713988W WO9806438A9 WO 1998006438 A9 WO1998006438 A9 WO 1998006438A9 US 9713988 W US9713988 W US 9713988W WO 9806438 A9 WO9806438 A9 WO 9806438A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- polymer network
- pharmaceutic composition
- pharmaceutic
- polymer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 364
- 229920000642 polymer Polymers 0.000 claims abstract description 359
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 54
- 230000000694 effects Effects 0.000 claims abstract description 46
- 230000004044 response Effects 0.000 claims abstract description 23
- 230000002776 aggregation Effects 0.000 claims abstract description 17
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract description 16
- 238000004220 aggregation Methods 0.000 claims abstract description 15
- 239000012528 membrane Substances 0.000 claims abstract description 14
- 230000003993 interaction Effects 0.000 claims abstract description 8
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 230000001747 exhibiting Effects 0.000 claims abstract description 3
- 239000000969 carrier Substances 0.000 claims abstract 2
- -1 polyoxyethylene Polymers 0.000 claims description 165
- 229920001983 poloxamer Polymers 0.000 claims description 113
- 229920001888 polyacrylic acid Polymers 0.000 claims description 91
- 229960000502 Poloxamer Drugs 0.000 claims description 88
- 239000000243 solution Substances 0.000 claims description 76
- 239000003814 drug Substances 0.000 claims description 72
- 229940079593 drugs Drugs 0.000 claims description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 64
- 230000002209 hydrophobic Effects 0.000 claims description 40
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 39
- 229920001451 Polypropylene glycol Polymers 0.000 claims description 32
- 239000000654 additive Substances 0.000 claims description 32
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 31
- 230000002441 reversible Effects 0.000 claims description 21
- 239000000178 monomer Substances 0.000 claims description 19
- 229940088597 Hormone Drugs 0.000 claims description 17
- 239000005556 hormone Substances 0.000 claims description 17
- 229920001577 copolymer Polymers 0.000 claims description 15
- 230000000996 additive Effects 0.000 claims description 13
- 229920001400 block copolymer Polymers 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229960005486 vaccines Drugs 0.000 claims description 10
- 239000003974 emollient agent Substances 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 8
- 239000004909 Moisturizer Substances 0.000 claims description 6
- 210000003491 Skin Anatomy 0.000 claims description 6
- 230000000843 anti-fungal Effects 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 6
- 230000001333 moisturizer Effects 0.000 claims description 6
- 239000004584 polyacrylic acid Substances 0.000 claims description 6
- 230000002335 preservative Effects 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 6
- 230000000202 analgesic Effects 0.000 claims description 5
- 230000001387 anti-histamine Effects 0.000 claims description 5
- 229940121375 antifungals Drugs 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 5
- 229940035676 ANALGESICS Drugs 0.000 claims description 4
- 229940074728 ANTIINFECTIVE OPHTHALMOLOGICS Drugs 0.000 claims description 4
- 229940021383 Antiinfective irrigating solutions Drugs 0.000 claims description 4
- 229960005475 Antiinfectives Drugs 0.000 claims description 4
- 229940035363 MUSCLE RELAXANTS Drugs 0.000 claims description 4
- 229940083876 Muscle relaxants FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims description 4
- 150000003926 acrylamides Chemical class 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 230000001773 anti-convulsant Effects 0.000 claims description 4
- 230000002924 anti-infective Effects 0.000 claims description 4
- 230000001754 anti-pyretic Effects 0.000 claims description 4
- 230000002921 anti-spasmodic Effects 0.000 claims description 4
- 239000001961 anticonvulsive agent Substances 0.000 claims description 4
- 239000002221 antipyretic Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000000850 decongestant Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000003158 myorelaxant agent Substances 0.000 claims description 4
- 239000002736 nonionic surfactant Substances 0.000 claims description 4
- 230000002936 tranquilizing Effects 0.000 claims description 4
- 239000003204 tranquilizing agent Substances 0.000 claims description 4
- 229940030606 DIURETICS Drugs 0.000 claims description 3
- MNQYNQBOVCBZIQ-JQOFMKNESA-A Sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims description 3
- 229960004291 Sucralfate Drugs 0.000 claims description 3
- 239000003159 antacid agent Substances 0.000 claims description 3
- 230000001458 anti-acid Effects 0.000 claims description 3
- 230000001396 anti-anti-diuretic Effects 0.000 claims description 3
- 230000001142 anti-diarrhea Effects 0.000 claims description 3
- 230000000840 anti-viral Effects 0.000 claims description 3
- 239000003793 antidiarrheal agent Substances 0.000 claims description 3
- 239000002579 antinauseant Substances 0.000 claims description 3
- 239000003699 antiulcer agent Substances 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 230000001624 sedative Effects 0.000 claims description 3
- 239000000932 sedative agent Substances 0.000 claims description 3
- 240000005497 Cyamopsis tetragonoloba Species 0.000 claims description 2
- 210000000214 Mouth Anatomy 0.000 claims description 2
- 208000003715 Parkinsonian Disorders Diseases 0.000 claims description 2
- 206010034010 Parkinsonism Diseases 0.000 claims description 2
- ATMLPEJAVWINOF-UHFFFAOYSA-N acrylic acid acrylic acid Chemical compound OC(=O)C=C.OC(=O)C=C ATMLPEJAVWINOF-UHFFFAOYSA-N 0.000 claims description 2
- 230000003262 anti-osteoporosis Effects 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims description 2
- 229920003086 cellulose ether Polymers 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 230000003547 miosis Effects 0.000 claims description 2
- 239000003604 miotic agent Substances 0.000 claims description 2
- 125000005702 oxyalkylene group Chemical group 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims description 2
- 239000003433 contraceptive agent Substances 0.000 claims 3
- 229940069428 ANTACIDS Drugs 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- 229940029985 MINERAL SUPPLEMENTS Drugs 0.000 claims 2
- 229940029983 VITAMINS Drugs 0.000 claims 2
- NLVXSWCKKBEXTG-UHFFFAOYSA-N Vinylsulfonic acid Chemical class OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 claims 2
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 2
- 230000000151 anti-reflux Effects 0.000 claims 2
- PVEOYINWKBTPIZ-UHFFFAOYSA-N but-3-enoic acid Chemical compound OC(=O)CC=C PVEOYINWKBTPIZ-UHFFFAOYSA-N 0.000 claims 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 2
- 230000003054 hormonal Effects 0.000 claims 2
- 239000008141 laxative Substances 0.000 claims 2
- 230000002475 laxative Effects 0.000 claims 2
- 235000020786 mineral supplement Nutrition 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 229930003231 vitamins Natural products 0.000 claims 2
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-Vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 claims 1
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001760 anti-analgesic Effects 0.000 claims 1
- 230000000111 anti-oxidant Effects 0.000 claims 1
- 230000000656 anti-yeast Effects 0.000 claims 1
- 229940006133 antiglaucoma drugs and miotics Carbonic anhydrase inhibitors Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229940121357 antivirals Drugs 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 239000003688 hormone derivative Substances 0.000 claims 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims 1
- 125000005395 methacrylic acid group Chemical class 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 claims 1
- 150000002894 organic compounds Chemical class 0.000 claims 1
- 229940026754 topical Antivirals Drugs 0.000 claims 1
- 150000003673 urethanes Chemical class 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 76
- 239000000463 material Substances 0.000 description 47
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 30
- 229960005309 Estradiol Drugs 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 239000000499 gel Substances 0.000 description 26
- 238000002156 mixing Methods 0.000 description 23
- 238000001879 gelation Methods 0.000 description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 21
- 239000012071 phase Substances 0.000 description 21
- 229920005862 polyol Polymers 0.000 description 21
- 239000008367 deionised water Substances 0.000 description 20
- 239000004615 ingredient Substances 0.000 description 19
- 150000003077 polyols Chemical class 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 238000007792 addition Methods 0.000 description 18
- 210000004027 cells Anatomy 0.000 description 18
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 17
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 239000000186 progesterone Substances 0.000 description 17
- 229960003387 progesterone Drugs 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 15
- 238000005063 solubilization Methods 0.000 description 15
- 108010073521 Luteinizing Hormone Proteins 0.000 description 14
- 229940040129 Luteinizing Hormone Drugs 0.000 description 14
- 102000009151 Luteinizing Hormone Human genes 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 235000002639 sodium chloride Nutrition 0.000 description 14
- 230000037250 Clearance Effects 0.000 description 13
- 102000016943 Muramidase Human genes 0.000 description 13
- 108010014251 Muramidase Proteins 0.000 description 13
- 230000035512 clearance Effects 0.000 description 13
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 13
- 229920001992 poloxamer 407 Polymers 0.000 description 13
- 210000001519 tissues Anatomy 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- ROOXNKNUYICQNP-UHFFFAOYSA-N Ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000004325 lysozyme Substances 0.000 description 12
- 235000010335 lysozyme Nutrition 0.000 description 12
- 229960000274 lysozyme Drugs 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 12
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 12
- 102000001554 Hemoglobins Human genes 0.000 description 11
- 108010054147 Hemoglobins Proteins 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000036912 Bioavailability Effects 0.000 description 10
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 10
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 230000000975 bioactive Effects 0.000 description 10
- 230000035514 bioavailability Effects 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 241000283898 Ovis Species 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 9
- 238000005755 formation reaction Methods 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 239000000017 hydrogel Substances 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 238000001816 cooling Methods 0.000 description 8
- 239000003999 initiator Substances 0.000 description 8
- 238000011068 load Methods 0.000 description 8
- 239000000693 micelle Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000002194 synthesizing Effects 0.000 description 8
- 210000003238 Esophagus Anatomy 0.000 description 7
- 229940015001 Glycerin Drugs 0.000 description 7
- 210000003928 Nasal Cavity Anatomy 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 229960005150 glycerol Drugs 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000002562 thickening agent Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- 239000006196 drop Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 206010067647 Delivery Diseases 0.000 description 5
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 210000004379 Membranes Anatomy 0.000 description 5
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 125000004432 carbon atoms Chemical group C* 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 230000004059 degradation Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000001419 dependent Effects 0.000 description 5
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 230000002633 protecting Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 230000001954 sterilising Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000000699 topical Effects 0.000 description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical group N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 4
- 230000035639 Blood Levels Effects 0.000 description 4
- SNPLKNRPJHDVJA-UHFFFAOYSA-N DL-Panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 210000000744 Eyelids Anatomy 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 210000004400 Mucous Membrane Anatomy 0.000 description 4
- PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000001580 bacterial Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 230000005587 bubbling Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000003628 erosive Effects 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 150000004676 glycans Polymers 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000000977 initiatory Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000015110 jellies Nutrition 0.000 description 4
- 239000008274 jelly Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 150000004804 polysaccharides Polymers 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 230000000717 retained Effects 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 230000003068 static Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 229960004791 tropicamide Drugs 0.000 description 4
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 3
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229940117927 Ethylene Oxide Drugs 0.000 description 3
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 3
- UQEAIHBTYFGYIE-UHFFFAOYSA-N Hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 229960000282 Metronidazole Drugs 0.000 description 3
- 210000001331 Nose Anatomy 0.000 description 3
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 3
- 230000037165 Serum Concentration Effects 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000010928 TGA analysis Methods 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 3
- 230000036526 Transport Rate Effects 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000004164 analytical calibration Methods 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000000845 anti-microbial Effects 0.000 description 3
- 230000001139 anti-pruritic Effects 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 230000003115 biocidal Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003093 cationic surfactant Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 229960005408 deslorelin Drugs 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 230000002255 enzymatic Effects 0.000 description 3
- VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 239000012527 feed solution Substances 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000001976 improved Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 229940079866 intestinal antibiotics Drugs 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 230000002035 prolonged Effects 0.000 description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 230000003381 solubilizing Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- 239000011778 trisodium citrate Substances 0.000 description 3
- 235000019263 trisodium citrate Nutrition 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- NECRQCBKTGZNMH-UHFFFAOYSA-N 3,5-dimethylhex-1-yn-3-ol Chemical compound CC(C)CC(C)(O)C#C NECRQCBKTGZNMH-UHFFFAOYSA-N 0.000 description 2
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 2
- 229940030600 ANTIHYPERTENSIVES Drugs 0.000 description 2
- 229940060228 Afrin Drugs 0.000 description 2
- 229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 description 2
- 229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- OZAIFHULBGXAKX-VAWYXSNFSA-N Azobisisobutyronitrile Chemical compound N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 2
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 2
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 2
- 101700001721 CT11 Proteins 0.000 description 2
- 102400000113 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infection Diseases 0.000 description 2
- 229940107161 Cholesterol Drugs 0.000 description 2
- 210000004087 Cornea Anatomy 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N Esomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 229940064258 Estrace Drugs 0.000 description 2
- 229940011871 Estrogens Drugs 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 229960004666 Glucagon Drugs 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 244000043158 Lens esculenta Species 0.000 description 2
- 229940087857 Lupron Drugs 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- 210000002850 Nasal Mucosa Anatomy 0.000 description 2
- 229940087419 Nonoxynol-9 Drugs 0.000 description 2
- FBWNMEQMRUMQSO-UHFFFAOYSA-N Nonoxynol-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N Oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000048284 Potato virus P Species 0.000 description 2
- 229940063238 Premarin Drugs 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229940030484 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Drugs 0.000 description 2
- 229940047670 SODIUM ACRYLATE Drugs 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N Sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M Sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 229920002359 Tetronic® Polymers 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical class [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 230000036462 Unbound Effects 0.000 description 2
- 206010062167 Vaginitis bacterial Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000844 anti-bacterial Effects 0.000 description 2
- 230000001078 anti-cholinergic Effects 0.000 description 2
- 230000001430 anti-depressive Effects 0.000 description 2
- 230000003276 anti-hypertensive Effects 0.000 description 2
- 230000000561 anti-psychotic Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 230000004397 blinking Effects 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 230000001804 emulsifying Effects 0.000 description 2
- 229940046080 endocrine therapy drugs Estrogens Drugs 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229920000578 graft polymer Polymers 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 230000000147 hypnotic Effects 0.000 description 2
- 239000003326 hypnotic agent Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001050 lubricating Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 230000003020 moisturizing Effects 0.000 description 2
- 230000003232 mucoadhesive Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000002911 mydriatic Effects 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000000133 nasal decongestant Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 229920004918 nonoxynol-9 Polymers 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000023 polynucleotide Polymers 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- MBHCWRKFAXKMRT-UHFFFAOYSA-N propanoic acid;1-tetradecoxytetradecane Chemical compound CCC(O)=O.CCCCCCCCCCCCCCOCCCCCCCCCCCCCC MBHCWRKFAXKMRT-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000002522 swelling Effects 0.000 description 2
- 230000002277 temperature effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- PRZXEPJJHQYOGF-GNAZCLTHSA-N (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one;nitric acid Chemical compound O[N+]([O-])=O.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C PRZXEPJJHQYOGF-GNAZCLTHSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
- LGJCFVYMIJLQJO-UHFFFAOYSA-N 1-dodecylperoxydodecane Chemical compound CCCCCCCCCCCCOOCCCCCCCCCCCC LGJCFVYMIJLQJO-UHFFFAOYSA-N 0.000 description 1
- BALXAMAFSGBZFN-UHFFFAOYSA-N 1-nonyl-2-(2-nonylphenoxy)benzene Chemical compound CCCCCCCCCC1=CC=CC=C1OC1=CC=CC=C1CCCCCCCCC BALXAMAFSGBZFN-UHFFFAOYSA-N 0.000 description 1
- 150000000319 19-nortestosterones Chemical class 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical class CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- LXOFYPKXCSULTL-UHFFFAOYSA-N 2,4,7,9-tetramethyldec-5-yne-4,7-diol Chemical compound CC(C)CC(C)(O)C#CC(C)(O)CC(C)C LXOFYPKXCSULTL-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-TUJWMRSMSA-N 2-[(2S)-butan-2-yl]-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-TUJWMRSMSA-N 0.000 description 1
- BLXVTZPGEOGTGG-UHFFFAOYSA-N 2-[2-(4-nonylphenoxy)ethoxy]ethanol Chemical group CCCCCCCCCC1=CC=C(OCCOCCO)C=C1 BLXVTZPGEOGTGG-UHFFFAOYSA-N 0.000 description 1
- HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 description 1
- KMNCBSZOIQAUFX-UHFFFAOYSA-N 2-ethoxy-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(OCC)C(=O)C1=CC=CC=C1 KMNCBSZOIQAUFX-UHFFFAOYSA-N 0.000 description 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-Hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- SUXLANSZRSDYOX-UHFFFAOYSA-N 4-[6-(4-carbamimidoylphenoxy)hexoxy]benzenecarboximidamide;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 SUXLANSZRSDYOX-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 229940030486 ANDROGENS Drugs 0.000 description 1
- 229940035674 ANESTHETICS Drugs 0.000 description 1
- 229940005486 ANTIMIGRAINE PREPARATIONS Drugs 0.000 description 1
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 description 1
- 229940005529 ANTIPSYCHOTICS Drugs 0.000 description 1
- 206010000496 Acne Diseases 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 229940062527 Alendronate Drugs 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N Angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N Antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 229940088710 Antibiotic Drugs 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229940095077 BEHENTRIMONIUM METHOSULFATE Drugs 0.000 description 1
- 108060001001 BRK1 Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N Bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 description 1
- 229940037530 COUGH AND COLD PREPARATIONS Drugs 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- JNIIDKODPGHQSS-DHDCSXOGSA-N Capreomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)C(CNC(=O)CC(N)CCCN)NC(=O)C(CO)NC(=O)C(N)CNC(=O)C1C1NC(N)=NCC1 JNIIDKODPGHQSS-DHDCSXOGSA-N 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229960003260 Chlorhexidine Drugs 0.000 description 1
- 229960004475 Chlortetracycline Drugs 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 229960001380 Cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N Cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N Cinnamic acid Chemical compound OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 230000035700 Clearance Rate Effects 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002286 Clodronic Acid Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N Clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229940108066 Coal Tar Drugs 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229940009997 Cromolyn Drugs 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 229940039227 DIAGNOSTIC AGENTS Drugs 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Didronel Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 206010013023 Diphtheria Diseases 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229960003913 Econazole Drugs 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N Econazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 229960001348 Estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N Estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- HZEQBCVBILBTEP-ZFINNJDLSA-N Estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 description 1
- 229960000285 Ethambutol Drugs 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N Ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- 239000005977 Ethylene Chemical group 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N Ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229940009626 Etidronate Drugs 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N Famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 Famotidine Drugs 0.000 description 1
- CRDAMVZIKSXKFV-YFVJMOTDSA-N Farnesol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO CRDAMVZIKSXKFV-YFVJMOTDSA-N 0.000 description 1
- 229940043259 Farnesol Drugs 0.000 description 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N Felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N Fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101710044881 GHRH Proteins 0.000 description 1
- 208000009471 Gastroesophageal Reflux Diseases 0.000 description 1
- 206010017885 Gastrooesophageal reflux disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 229940094892 Gonadotropins Drugs 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102000038586 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 208000005252 Hepatitis A Diseases 0.000 description 1
- 208000002672 Hepatitis B Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N Hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000006572 Human Influenza Diseases 0.000 description 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 102100011311 KNG1 Human genes 0.000 description 1
- FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 description 1
- 108010003195 Kallidin Proteins 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N Ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 229940045505 Klebsiella pneumoniae Drugs 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- 229920000126 Latex Polymers 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N Levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 229960000831 Levobunolol Drugs 0.000 description 1
- 229960005015 Local anesthetics Drugs 0.000 description 1
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 1
- 229940074734 MYDRIATICS AND CYCLOPLEGICS Drugs 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- 241000539716 Mea Species 0.000 description 1
- MHIGBKBJSQVXNH-IWVLMIASSA-N Metacycline Chemical compound C=C([C@H]1[C@@H]2O)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O MHIGBKBJSQVXNH-IWVLMIASSA-N 0.000 description 1
- 229940042016 Methacycline Drugs 0.000 description 1
- 229960004011 Methenamine Drugs 0.000 description 1
- 229960005040 Miconazole Nitrate Drugs 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 229940042472 Mineral Oil Drugs 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 229940010383 Mycobacterium tuberculosis Drugs 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- YDXZSNHARVUYNM-UHFFFAOYSA-N N-[4-chloro-3-(trifluoromethyl)phenyl]-2-ethoxybenzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 YDXZSNHARVUYNM-UHFFFAOYSA-N 0.000 description 1
- 229940097496 Nasal Spray Drugs 0.000 description 1
- 229960000808 Netilmicin Drugs 0.000 description 1
- 231100000618 Neurotoxin Toxicity 0.000 description 1
- 229960002715 Nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229940053934 Norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N Norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229960001180 Norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N Norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229910004354 OF 20 W Inorganic materials 0.000 description 1
- 229940074730 OPHTHAMOLOGIC DIAGNOSTIC AGENTS Drugs 0.000 description 1
- 229940005483 OPIOID ANALGESICS Drugs 0.000 description 1
- 101710008205 OXT Proteins 0.000 description 1
- 102100017240 OXT Human genes 0.000 description 1
- 230000035536 Oral bioavailability Effects 0.000 description 1
- 229960005162 Oxymetazoline hydrochloride Drugs 0.000 description 1
- 229960000625 Oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N Oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 Oxytocin Drugs 0.000 description 1
- 229940093766 PEG-60 LANOLIN Drugs 0.000 description 1
- 102100008873 POMC Human genes 0.000 description 1
- 108060006375 POMC Proteins 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940101267 Panthenol Drugs 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N Pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 Pentamidine Drugs 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- IWHCAJPPWOMXNW-LYKMMFCUSA-N Peptide T Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 IWHCAJPPWOMXNW-LYKMMFCUSA-N 0.000 description 1
- 108010071384 Peptide T Proteins 0.000 description 1
- 102100011271 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N Pheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- 229960001190 Pheniramine Drugs 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N Phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 229960005323 Phenoxyethanol Drugs 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 229960001963 Pilocarpine Nitrate Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N Pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 229920002257 Plurafac® Polymers 0.000 description 1
- 229920002012 Pluronic® F 38 Polymers 0.000 description 1
- 229920002025 Pluronic® F 88 Polymers 0.000 description 1
- 229920002004 Pluronic® R Polymers 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229940044476 Poloxamer 407 Drugs 0.000 description 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 229940087096 RICINOLEAMIDOPROPYL ETHYLDIMONIUM ETHOSULFATE Drugs 0.000 description 1
- 229960001487 RIMEXOLONE Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N Ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 Ranitidine Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N Rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 229940101011 SODIUM HYDROXYMETHYLGLYCINATE Drugs 0.000 description 1
- 229950005137 Saperconazole Drugs 0.000 description 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N Selenium Sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229960000553 Somatostatin Drugs 0.000 description 1
- IJCWFDPJFXGQBN-BIFNRIDTSA-N Sorbitan tristearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-BIFNRIDTSA-N 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229940064707 Sympathomimetics Drugs 0.000 description 1
- 229940111630 Tea Tree Oil Drugs 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N Terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 229940019375 Tiludronate Drugs 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 229960005221 Timolol Maleate Drugs 0.000 description 1
- 229960000707 Tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- 229940035670 Tuftsin Drugs 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N Tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 229940044959 Vaginal Cream Drugs 0.000 description 1
- 229940120293 Vaginal Suppository Drugs 0.000 description 1
- 239000004164 Wax ester Chemical class 0.000 description 1
- 208000001877 Whooping Cough Diseases 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- ZGIGZINMAOQWLX-NCZFFCEISA-N [(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl] acetate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\COC(C)=O ZGIGZINMAOQWLX-NCZFFCEISA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive Effects 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 229940053550 agents used for ADHD and nootropics psychostimulants Xanthine derivatives Drugs 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000004931 aggregating Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N al2o3 Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000578 anorexic Effects 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- 230000000507 anthelmentic Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic Effects 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000002456 anti-arthritic Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003474 anti-emetic Effects 0.000 description 1
- 230000000118 anti-eoplastic Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000000842 anti-protozoal Effects 0.000 description 1
- 230000002421 anti-septic Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 239000003160 antidiuretic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940053195 antiepileptics Hydantoin derivatives Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229910052454 barium strontium titanate Inorganic materials 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Chemical class 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzyl-dodecyl-dimethylazanium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- KQNZLOUWXSAZGD-UHFFFAOYSA-N benzylperoxymethylbenzene Chemical compound C=1C=CC=CC=1COOCC1=CC=CC=C1 KQNZLOUWXSAZGD-UHFFFAOYSA-N 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 230000003139 buffering Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000473 carbonimidoyl group Chemical group [H]\N=C(/*)* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940096384 chicken egg white lysozyme Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 229940035811 conjugated estrogens Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 239000011557 critical solution Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 230000001351 cycling Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- QIVLQXGSQSFTIF-UHFFFAOYSA-M docosyl(trimethyl)azanium;methyl sulfate Chemical compound COS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C QIVLQXGSQSFTIF-UHFFFAOYSA-M 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 229950008385 estrone sulphate Drugs 0.000 description 1
- 229940081345 estropipate Drugs 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- VDNMPXDJBJILBP-UNUNFZTGSA-N ethyl-[3-[[(Z,12R)-12-hydroxyoctadec-9-enoyl]amino]propyl]-dimethylazanium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)NCCC[N+](C)(C)CC VDNMPXDJBJILBP-UNUNFZTGSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 229960003472 felbamate Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 201000006860 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 229960001715 hexamidine isethionate Drugs 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 230000000887 hydrating Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 230000002218 hypoglycaemic Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 239000008206 lipophilic material Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 1
- 229940083747 low-ceiling diuretics Xanthine derivatives Drugs 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000005505 measles Diseases 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 230000036630 mental development Effects 0.000 description 1
- 229960003494 metacycline Drugs 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(1E)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 230000000116 mitigating Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229930015196 nicotine Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229960000993 norethisterone Drugs 0.000 description 1
- 230000003364 opioid Effects 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 230000036220 oral bioavailability Effects 0.000 description 1
- 101700057139 oxyT Proteins 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating Effects 0.000 description 1
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 201000005702 pertussis Diseases 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 238000005020 pharmaceutical industry Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000406 phosphotungstic acid polymer Polymers 0.000 description 1
- 201000010830 physical disease Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 230000001179 pupillary Effects 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 229960001141 pyrithione zinc Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2(1H)-one Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- ZZPKZRHERLGEKA-UHFFFAOYSA-N resorcinol monoacetate Chemical compound CC(=O)OC1=CC=CC(O)=C1 ZZPKZRHERLGEKA-UHFFFAOYSA-N 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001502 supplementation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001975 sympathomimetic Effects 0.000 description 1
- 230000035923 taste sensation Effects 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000001248 thermal gelation Methods 0.000 description 1
- 229960005324 tiludronic acid Drugs 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000000522 vaginal cream Substances 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000000261 vasodilator Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
Definitions
- the present invention relates to pharmaceutic compositions useful in a variety of pharmaceutical products and applications, and in particular, compositions useful transmucosal applications, such as esophageal, otic, vaginal, rectal, topical and ophthalmic. More particularly, the present invention is directed to a pharmaceutic composition for treating a disease or disorder comprising a polymer network that can be designed to reversibly gel over a wide range of conditions.
- bioavailability of the drug is very low due to, for example, the degradation of oral-delivered drugs by hepato-gastrointestinal first-pass elimination or rapid clearance of the drug from the site of application.
- the net result is that frequent dosing may be required with higher than needed amounts of drug, which can lead to undesired side effects.
- Hydrogels such as cellulosics
- a hydrogel is a polymer network which absorbs a large quantity of water without the polymer dissolving in water.
- the hydrophilic areas of the polymer chain absorb water and form a gel region. The extent of gelation depends upon the volume of the solution which the gel region occupies.
- Reversibly gelling solutions are known in which the solution viscosity increases and decreases with an increase and decrease in temperature, respectively. Such reversibly gelling systems are useful wherever it is desirable to handle a material in a fluid state, but performance is preferably in a gelled or more viscous state.
- a known material with these properties is a thermal setting gel using block copolymer polyols, available commercially as Pluronic® polyols (BASF,
- Tetronic® polyols Another known system which is liquid at room temperature, but forms a semi- solid when warmed to about body temperature is formed from tetrafunctional block polymers of polyoxyethylene and polyoxypropylene condensed with ethylenediamine, commercially available as Tetronic® polyols. These compositions are formed from approximately 10% to 50% by weight of the polyol in an aqueous medium. See, U.S. Patent No. 5,252,318.
- compositions including Pluronic® and Tetronic® polyols commercially available forms of poly(ethyleneoxide)/poly(propyleneoxide) block copolymers, significant increases in viscosity (5- to 8-fold) upon a simultaneous change in temperature and pH are observed only at much higher polymer levels. See, Figs. 3-6 of Joshi et al.
- WO 95/24430 disclose block and graft copolymers comprising a pH-sensitive polymer component and a temperature-sensitive polymer component.
- the block and graft copolymers are well-ordered and contain regularly repeating units of the pH-sensitive and temperature-sensitive polymer components.
- the copolymers are described as having a lower critical solution temperature (LCST), at which both solution-to-gel transition and precipitation phase transition occur.
- LCST critical solution temperature
- Light transmission is reduced, which may be undesirable in many applications, where the aesthetic characteristics of the composition are of some concern.
- the known systems which exhibit reversible gelation are limited in that they require large solids content and/or in that the increase in viscosity less desired.
- the reversibly gelling polymeric network of this invention has the physico-chemical characteristics that make it a suitable drug delivery vehicle for transmucosal delivery of conventional small chemical drugs as well as new macromolecular (e.g., peptides) drugs or therapeutic products.
- the reversibly gelling polymer network comprises a responsive polymer component capable of aggregation in response to an environmental stimulus.
- the responsive polymer component is randomly bonded to a structural polymer component which exhibits self-repulsive interactions over the use conditions of the pharmaceutical composition. The repulsive forces cause the structural component to remain extended and solvated in an aqueous medium.
- the reversibly gelling polymer network is characterized in that it viscosifies in response to the environmental stimulus.
- the polymer network may also include some unbound or "free" responsive polymer or other additives which contribute to or modify the characteristic properties of the polymer composition.
- the pharmaceutic composition includes a pharmaceutic agent selected to provide a preselected pharmaceutic effect.
- a pharmaceutic effect is one which seeks to treat the source or symptom of a disease or physical disorder.
- Pharmaceutics include those products subject to regulation under the FDA pharmaceutic guidelines, as well as consumer products.
- gelation or “viscosification” as those terms are used herein, it is meant a drastic increase in the viscosity of the polymer network solution. Gelation is dependent on the initial viscosity of the solution, but typically a viscosity increase at pH 7 and 1 wt% polymer concentration is in the range of preferably 2- to 100-fold, and preferably 5- to 50-fold, and more preferably 10- to 20-fold for a polymer network which is used in the preparation of the pharmaceutic compositions of the invention. Such effects are observed in a simple polymer network solution and the effect may be modified by the presence of other components in the pharmaceutic composition.
- reversibly gelling as that term is used herein, it is meant that the process of gelation takes place upon an increase in temperature rather than a decrease in temperature. This is counter-intuitive, since solution viscosity typically decreases with an increase in temperature.
- use conditions as that term is used herein it is meant all conditions to which the composition is likely to be exposed during its use, including during shipment and storage as well as during medical treatment.
- a typical reversibly gelling polymer network may be comprised of about 0.01 wt% to about 10 wt%, preferably less than about 4 wt% of total polymer solids (e.g., responsive polymer and structural polymer), and more preferably less than 1 wt% total polymer solids, while still exhibiting reverse thermal viscosification.
- the total solids content of the composition may be much higher.
- the viscosity of a 1 wt% polymer network increases at least ten-fold with an increase in temperature of about 5°C at pH 7. Viscosity increases may be even greater over a larger temperature range at pH 7 and or higher polymer network content.
- the relative proportion of responsive polymer and structural polymer may vary in the composition, dependent upon the desired properties of the pharmaceutic composition.
- the responsive polymer is present in a range of about 1 to 20 wt% and the structural polymer is present in a range about of 99 to 80 wt%.
- the responsive polymer component is present in a range of about 21 to 40 wt% and the structural polymer component is present in a range of about 79 to 60 wt%.
- the responsive polymer component is present in a range of about 41 to 50 wt% and the structural polymer component is present in a range of about 59 to 50 wt%.
- the responsive polymer component is present in a range of about 51 to 60 wt% and the structural polymer component is present in a range of about 49 to 40 wt%. In yet another embodiment, the responsive polymer component is present in a range of about 61 to 90 wt% and the structural polymer component is present in a range of about 39 to 20 wt%. In another embodiment, the responsive polymer component is present in a range of about 81 to 99 wt% and the structural polymer component is present in a range of about 19 to 1 wt%.
- the reversibly gelling polymer network described above may be included in a pharmaceutic composition as a delivery vehicle for a pharmaceutic agent.
- the reversibly gelling polymer network may be included to improve the flow characteristics, thickness and other properties of the composition.
- Additives also may be included to modify the polymer network performance, such as to increase or decrease the temperature of the liquid-to-gel transition and/or to increase or decrease the viscosity of the responsive polymer composition.
- the reversibly gelling polymer network is incorporated into a pharmaceutic composition to impart thickening properties to the composition at the use and/or application temperature.
- thickening properties include enhanced overall viscosity, as well as a desirable viscosity response with temperature.
- the polymer network may be useful as a thickener in pH ranges where other thickeners are not effective.
- the reversibly gelling polymer network is incorporated into a pharmaceutic composition to stabilize and solubilize hydrophobic agents in the pharmaceutic composition.
- the reversibly gelling polymer network may be included to increase emulsion stability.
- emulsions a suspension of small droplets or particles of a first material in a second material
- lose viscosity upon heating As will be demonstrated herein, the reversibly gelling polymer network retains its emulsifying properties even at elevated temperatures.
- the reversibly gelling polymer network may be included in the composition to impart emolliency to the composition.
- the composition may also act as a film-forming agent after it has been applied to the skin or other mucosal membrane. This film-forming agent may be used as a barrier to prevent water loss from the skin which contributes to the moisturization of the skin.
- the formed-film could also provide protective coating ("band-aid") to protect the tissue against environmental challenge(s) or to provide a mechanical separation between to adjust tissues (adhesion prevention).
- Figure 1 is a schematic illustration of the poloxamer:poly(acrylic acid) polymer network below and above the transition temperature illustrating the aggregation of the hydrophobic poloxamer regions;
- Figure 2 is a graph of viscosity vs. temperature for a 1 wt%, 2 wt% and 3 wt% responsive polymer network aqueous composition of a poloxamer/poly(acrylic acid) (1 : 1) at pH 7.0 measured at a shear rate of 0.44 sec "1 ;
- Figure 3 is a graph of viscosity vs. temperature for a 1 wt% poloxamer: poly(acrylic acid) polymer network composition demonstrating reversibility of the viscosity response;
- Figure 4 shows the viscosity response of a 2 wt% poloxamer:poly(acrylic acid) polymer composition at various shear rates
- Figure 5 shows a viscosity response curve for a 2 wt% poloxamer: poly(acrylic acid) polymer network composition prepared with nominal mixing and stirring and prepared using high shear homogenization (8000 rpm, 30 min);
- Figure 6 is a graph of viscosity vs. temperature for a 1 wt% poloxamer: poly(acrylic acid) polymer network composition at various pHs
- Figure 7 is a graph of viscosity vs. temperature for a 1 wt% poloxamer: poly(acrylic acid) polymer network composition with and without addition of 0.25 wt% KC1;
- Figure 8 is a graph of viscosity vs. temperature for a 1 wt% poloxamer: poly(acrylic acid) polymer network composition with and without addition of 0.5 wt% acetamide MEA;
- Figure 9 is a graph of viscosity vs. temperature for a 1 wt% poloxamer: poly(acrylic acid) polymer network composition without and with 5 wt%, 10 wt% and 20 wt% added ethanol, respectively;
- Figure 10 is a graph of viscosity vs. temperature for a 1 wt% poloxamer: poly(acrylic acid) polymer network composition without and with addition of 0.025 wt% Surfynol CT11 ;
- Figure 1 1 is an illustration of a reversibly gelling polymer network used as an emulsifier and stabilizer for a hydrophobic agent;
- Figure 12A is a plot of equilibrium solubility of estradiol in aqueous (pH 7.0) solutions of a reversibly gelling polymer network and Figure 10B a plot of the release of estradiol from the polymeric composition as a function of concentration;
- Figure 13A plot of equilibrium solubility of progesterone in aqueous (pH 7.0) solutions of a reversibly gelling polymer network and Figure 1 IB a plot of the release of progesterone from the polymeric composition as a function of concentration;
- Figure 14 is a plot of viscosity vs. temperature for (a) a 1 wt% responsive polymer network aqueous composition of Pluronic® F127 poloxamer/poly(acrylic acid) (1 : 1) and (b) a 1 wt% physical blend of Pluronic® F127 poloxamer/poly(acrylic acid) (1 :1) at pH 7.0 measured at a shear rate 0.22 sec "1 ;
- Figure 15 is a plot of viscosity vs. temperature for a 1 wt% responsive polymer network aqueous composition of Pluronic® F88 poloxamer/poly(acrylic acid) (1 : 1) at pH 7.0 measured at a shear rate 2.64 sec "1 ;
- Figure 16 is a graph of the viscosity vs. temperature effect for a responsive polymer network composition of 2 wt% Pluronic® PI 04 poloxamer/poly(acrylic acid) (1 :1) in deionized water at pH 7.0 measured at shear rate of 22 sec "1 ;
- Figure 17 is plot of viscosity vs. temperature for a responsive polymer network composition of 2 wt% Pluronic® F123 poloxamer/poly(acrylic acid) (1 :1) at pH 7.0 measured at a shear rate of 22 sec '1 ;
- Figure 18 is plot of viscosity vs. temperature for a responsive polymer network composition of 2 wt% Pluronic® F127/poly(acrylic acid-co-methacrylic acid) (1 :1) in deionized water at a shear rate of 22 sec "1 ;
- Figure 19 is a plot of viscosity vs. temperature for 1 wt% made of series of poloxamers and poly(acrylic acid) (1 : 1) in deionized water at a shear rate of 132 sec' 1 ;
- Figure 20 is a plot of viscosity vs. temperature for a responsive polymer network composition of a 2 wt% polyethyleneglycol mono(nonylphenylether)/ polyacrylic acid (1 :1) at pH 7.0 at a shear rate of 2.64 sec '1 ;
- Figure 21 is a plot showing release of hemoglobin from a poloxamer/poly(acrylic acid) polymer network of the invention.
- Figure 22 is a plot showing the release of lysozyme from the poloxamer/poly(acrylic acid) polymer complex of the invention
- Figure 23 is a plot showing release of insulin from a poloxamer/poly(acrylic acid) polymer network composition of the invention
- Figure 24 is a plot of viscosity vs. temperature for a poloxamer/poly(acrylic acid) polymer network composition (a) before and (b) after sterilization by autoclave;
- Figure 25 is a plot of the effect of loading fluorescein on the onset of gelation of responsive polymer network vs. total polymer concentration in responsive polymer network solution (pH 7.0);
- Figure 26 is a plot of the rate of progesterone release and macroscopic viscosity vs. polymer concentration
- Figure 27 is a plot of the percentage of progesterone release vs. polymer concentration in responsive polymer network
- Figure 28 is a plot of fluorescein retention in rabbit eye vs. time for a 1 wt% poloxamer:poly(acrylic acid) polymer network;
- Figure 29 is a scintigraphic assessment of corneal residence time in human and rabbit eyes, which compares residence time for a poloxamer:poly(acrylic acid) composition with that of commercially available materials;
- Figure 30 is a plot of activity vs. time to determine retention time of a nasal composition of the invention in the nasal passages;
- Figure 31 is a plot of serum concentration of luteinizing hormone in sheep administered nasally from a 5.5 wt% solution of a poloxamer:poly(acrylic acid) polymeric network containing 100 ⁇ g of a GnRH analog;
- Figure 32 is a plot of activity vs. time to determine retention time of a nasal composition of the invention in the esophageal passages;
- Figure 33 is a plot of cumulative serum estradiol levels vs. time following vaginal delivery of estrogens in sheep using a poloxamer:poly(acrylic acid) polymeric delivery vehicle;
- Figure 34 is a plot of serum luteinizing hormone levels vs. time following vaginal delivery of GnRH and its analogs in sheep using a poloxamer:poly(acrylic acid) polymeric delivery vehicle.
- the present invention is directed to a pharmaceutic composition
- a novel responsive component:structural component polymer network comprising a novel responsive component:structural component polymer network.
- the polymer network functions as an environmentally sensitive thickening agent, and in addition possesses surfactant and emulsifying capabilities which may be beneficial to the pharmaceutic composition.
- the polymer network composition according to the invention includes a responsive polymer component randomly covalently bonded to a structural polymer component.
- the polymer network contains about 0.01-20 wt% each of responsive polymer and structural polymer.
- Exemplary polymer network compositions range from about 1 :10 to about 10:1 responsive polyme ⁇ structural polymer.
- Polymer network gel compositions which exhibit a reversible gelation at body temperature (25-40°C) and/or at physiological pH (ca. pH 3.0-9.0) and even in basic environments up to pH 13 (e.g., the gasto-intestinal environment) are particularly preferred for pharmaceutic applications.
- compositions of the invention include a safe and effective amount of a pharmaceutically active agent.
- Safe and effective means an amount high enough to significantly positively modify the condition to be treated or the pharmaceutic effect to be obtained, but low enough to avoid serious side effects.
- the responsive component is an oligomer or polymer which will respond to a stimulus to change its degree of association and/or agglomeration.
- the stimulus may be temperature, pH, ionic concentration, solvent concentration, light, magnetic field, electrical field, pressure or other triggers commonly used to trigger a responsive gel material. Temperature is a preferred environmental trigger.
- the aggregation may be in the form of micelle formation, precipitation, labile crosslinking or other factors.
- the responsive component typically possesses regions of hydrophobic character, e.g., poly(propyleneoxide) blocks, and hydrophilic character, e.g., poly(ethyleneoxide) blocks in order to facilitate aggregation.
- the responsive polymer may be linear or branched.
- Suitable responsive components include polyoxyalkylene polymers, such as block copolymers of different oxyalkylene units. At least one polyoxyalkylene unit should have hydrophobic characteristics and at least one polyoxyalkylene unit should have hydrophilic characteristics.
- a block copolymer of polyoxyethylene and polyoxypropylene may be used in a preferred embodiment of the invention.
- Pluronic® (BASF) triblock polymers are commercially available for a in the range of 16 to 48 and b ranging from 54-62.
- alkyl polyols which are a product of alcohol condensation reactions with a terminal alkyl or arylalkyl group.
- the alkyl group should have hydrophobic character, such as butyl, hexyl and the like.
- An alkyl polyol may have the general formula R-(OCH 2 CH 2 ) n OH, where R is a nonpolar pendant group such as alkyl and arylalkyl and the like, and n is in the range of 5-1000.
- a preferred alkylpolyol is polyethyleneglycol mono(nonylphenyl)ether.
- Still other exemplary responsive components may include cellulosic, cellulose ethers and guar gums which possess hydrophobic and hydrophilic regions along the polymer backbone which permit aggregation behavior.
- One or more responsive components may be used in the reversibly gelling polymer network composition of the present invention.
- the structural component is an oligomer or polymer which serves as a support for the responsive polymer so that a multi-component polymer network is formed.
- the structural component experiences self-repulsive interactions, that is. the structural polymer tends to repel rather than attract like structural polymer components. This results in an extended structural polymer.
- the structural component exhibits such repulsive interactions over the entire use conditions of the polymer network.
- the structural component unlike the responsive component of the polymer network which exists in two different states, e.g., aggregated and non-aggregated, dependent upon its environment, the structural component remains in a substantially extended over the entire use condition of the composition.
- Suitable structural components include ionizable polymers. Ionization provides the repulsive self-interactions which characterize the structural polymer component.
- the ionizable polymers of the present invention include linear, branched and/or crosslinked polymers. Of particular interest are carboxyvinyl polymers of monomers such as acrylic acid, methacrylic acid, ethacrylic acid, phenyl acrylic acid, pentenoic acid and the like. Poly(acrylic acid) and its salts is a preferred carboxyvinyl polymer.
- One or more poly(carboxyvinyl) polymers may be used in the responsive polymer network compositions of the present invention.
- Copolymers such as by way of example only, copolymers of acrylic acid and methacrylic acid, are also contemplated.
- Naturally occurring polymers such as chitosan or hyaluronic acids are also possible as structural polymers since they are capable of forming an ionized network as polymers or copolymers of other structural polymers.
- Non-ionized polymers which contain both hydrophilic and hydrophobic groups may be suitable structural polymers where they exhibit sufficient repulsive forces over use conditions to maintain the polymer extended in solution.
- Suitable non-ionized structural polymers include, acrylamides or substituted acrylamides.
- the poly(acrylic acid) may be linear, branched and/or crosslinked.
- Poly(acrylic acid) is capable of ionization with a change in pH of the solution.
- ionization as that term is used with respect to poly(acrylic acid), it is meant the formation of the conjugate base of the acrylic acid, namely acrylate.
- poly(acrylic acid) includes both ionized and non-ionized versions of the polymer. Changes in ionic strength may be accomplished by a change in pH or by a change in salt concentration.
- the viscosifying effect of the polymer network is partly a function of the ionization of the poly(acrylic acid); however, reverse thermal gelling may occur without ionization.
- the reversibly gelling responsive polymer networks compositions of the present invention are highly stable and do not exhibit any phase separation upon standing or upon repeated cycling between a liquid and a gel state. Samples were stored at 45 °C for more than three months without any noticeable decomposition, clouding, phase separation or degradation of gelation properties. This is in direct contrast to polymer blends and aqueous mixed polymer solutions, where phase stability and phase separation is a problem, particularly where the constituent polymers are immiscible in one another.
- the structure of the polymer network involves a random bonding of the responsive polymer component onto the backbone of an extended, well solvated structural polymer component.
- the combination of the structural polymer component and randomly bonded responsive polymer component gives the composition its unique properties. Viscosity is a function of the molecular weight of the solubilized polymer. Aggregation of the responsive polymer component increases the effective molecular weight of the polymer network. The aggregation may be in the form of micelle formation, precipitation, labile crosslinking or other factors.
- the repulsive forces of the structural polymer component keeps the polymer in an extended, solvated state which prevents precipitation upon the effective increase in molecular weight.
- the observed thermal behavior of the reversibly gelling polymer network suggests that the increase in viscosity is due to aggregation of the hydrophobic portion of the poloxamer at the transition temperature which, because of bonding with the poly(acrylic acid) component, serve as temporary cross-links which physically bridge adjacent chains of poly(acrylic acid) to provide a viscous gel-like extended polymer structure.
- the aggregation process may be understood as occurring as shown in Figure 1, in which a backbone 20 represent poly(acrylic acid), a thin band 24 represents the hydrophobic poly(propyleneoxide) region of the poloxamer and a thick band 26 represents the hydrophilic poly(ethyleneoxide) region of the poloxamer.
- a backbone 20 represent poly(acrylic acid)
- a thin band 24 represents the hydrophobic poly(propyleneoxide) region of the poloxamer
- a thick band 26 represents the hydrophilic poly(ethyleneoxide) region of the poloxamer.
- the polymer network is randomly arranged, as is shown in Figure 1A.
- the hydrophobic regions 24 associate to form aggregations or micelles 28, as is shown in Figure IB. The association increases the effective molecular weight of the polymer network composition with the corresponding increase in viscosity.
- the reverse viscosification effect at low polymer concentrations provides clear, colorless gels which are particularly well-suited to pharmaceutic applications. For example, very little residue is formed upon dehydration which may be important in some applications, such as in optically applied pharmaceutics.
- An additional advantage of the polymer network of the invention is that it remains clear and translucent before and after the triggering environmental change. These characteristics of the reversibly gelling polymer network make it well suited for use in pharmaceutic compositions.
- the practical advantage of this behavior of the composition is that the formulation can be administered as a flowing liquid at ambient temperatures. Upon contact with body tissues it viscosifies, thus changing its flow properties, and more importantly, its clearance from the site of application. Furthermore, for polymers in general, the viscosity at ambient temperature is concentration dependent. As the concentration is increased to achieve desired flow properties in contact with body tissues, the viscosity at ambient temperatures also increases, making it more difficult to administer such compositions.
- the uniqueness of the polymeric network of this invention also allows it to the administered easily at ambient temperatures as a flowing liquid at various concentrations; its gelled state is only realized once it has been placed in contact with body tissues.
- a composition may be prepared at low temperatures while the polymer network is in a low viscosity state. Mixing of ingredients under low viscosity is expected to be easier, thus simplifying the manufacturing process. Yet, the resultant mixture would be of increased viscosity at use temperatures.
- a pharmaceutic composition comprising reversibly gelling polymer network may be spread thinly to allow for even application, due to its low viscosity at room temperature, but will thicken and "fill" the body contours upon warming up to body surface temperature.
- the reversibly gelling polymer network may also be included in a pharmaceutic composition for use as a stabilizing, solubilizing or emulsifying agent for a hydrophobic component of the pharmaceutic formulation.
- a pharmaceutic composition for use as a stabilizing, solubilizing or emulsifying agent for a hydrophobic component of the pharmaceutic formulation.
- hydrophobic domains are created which may be used to solubilize and control release of hydrophobic agents.
- Similar micelle-based systems have been shown to protect trapped peptides and proteins against enzymatic degradation from surface enzymes.
- Figure 2 is a graph of viscosity vs. temperature for 1 wt%, 2 wt% and 3 wt% polymer network compositions comprising 1 :1 poloxamer:poly(acrylic acid), hydrated and neutralized.
- the viscosity measurements were taken on a Brookfield viscometer at a shear rate of 0.44 sec '1 at pH 7.0. All solutions had an initial viscosity of about 1080 cP and exhibited a dramatic increase in viscosity to gel point at about 35°C.
- the viscosity response is consistent up to 24 °C; however, the final viscosity is reduced with increasing shear rate.
- the polymeric network behaves approximately like a Newtonian liquid - very little shear thinning is observed in the available shear range. As the temperature and the viscosity increases, so does the shear thinning.
- High temperature, high shear rate data can fitted with a power law model, ⁇ « ⁇ n" ' where ⁇ and ⁇ are the viscosity and the shear rate, respectively.
- the responsive component: structural component polymer network composition does not permanently loose viscosity after being subjected to high shear conditions.
- the polymer network composition remains unaffected by such shear conditions as homogenization.
- Figure 5 compares the viscosity response curve of a 2 wt% poloxamer:poly(acrylic acid) polymer composition prepared with nominal mixing (simple line) and stirring with that of a polymer composition of similar composition prepared using high shear homogenization designated by a ticked line (8000 rpm, 30 min). No significant decrease in viscosity is observed. The practical implication of this effect is that the polymeric network compositions can be delivered even at high temperatures if sufficiently high shear is available.
- the shear thinning behavior also allows for the composition to be spread across the precorneal surface of the eye as a result of the shearing effect of the movement of the eyelids.
- the composition may also be applied through a nozzle that provides high shear to reduce viscosity, yet the composition regains its viscosity after application to the treatment area. This contrasts with conventional formulations which permanently lose viscosity after being subjected to high shear.
- a number of factors influence the viscosity and transition temperature of the composition. The more important factors include polymer concentration, pH and presence and nature of additives.
- the pharmaceutical composition may also include additives for influencing the performance of the polymer network, such as the transition temperature and the viscosity of the polymer composition above the transition temperature.
- additives for influencing the performance of the polymer network such as the transition temperature and the viscosity of the polymer composition above the transition temperature.
- the following list is not intended to be exhaustive but rather illustrative of the broad variety of additives which can be used.
- solvents e.g., 2-propanol, ethanol, acetone, 1,2- pyrrolidinone, N-methylpyrrolidinone
- salts e.g., calcium chloride, sodium chloride, potassium chloride, sodium or potassium phosphates, borate buffers, sodium citrate
- preservatives benzalkonium chloride, phenoxyethanol, sodium hydroxymethylglycinate, ethylparaben, benzoyl alcohol, methylparaben, propylparaben, butylparaben, Germaben II
- humectant/moisturizers acetamide MEA, lactimide MEA, hydrolyzed collagen, mannitol, panthenol, glycerin
- lubricants hyaluronic acid, mineral oil, PEG-60-lanolin, PPG-12-PEG-50-lanolin, PPG-2 myristyl ether propionate
- surfactants e.g., 2-
- Surfactants may be divided into three classes: cationic, anionic, and nonionics.
- An example of a cationic surfactant used is ricinoleamidopropyl ethyldimonium ethosulfate (Lipoquat R).
- Anionic surfactants include sodium dodecyl sulfate and ether sulfates such as Rhodapex CO-436.
- Nonionic surfactants include Surfynol CT-111, TG, polyoxyethylene sorbitan fatty acid esters such as Tween 65 and 80, sorbitan fatty acid esters such as Span 65, alkylphenol ethoxylates such as Igepal CO-210 and 430, dimethicone copolyols such as Dow Corning 190, 193, and Silwet L7001.
- polymers including xanthan gum, cellulosics such as hydroxyethylcellulose (HEC), carboxymethoxycellulose (CMC), lauryldimonium hydroxypropyl oxyethyl cellulose (Crodacel QL), hydroxypropylcellulose (HPC), and hydroxypropylmethylcellulose (HPMC), poly(acrylic acid), cyclodextrins, methyl acrylamido propyl triammonium chloride (MAPTAC), polyethylene oxide, polyvinylpyroliddone, polyvinyl alcohol, and propylene oxide/ethylene oxide random copolymers. Poloxamers may also be used as additives.
- HEC hydroxyethylcellulose
- CMC carboxymethoxycellulose
- Crodacel QL lauryldimonium hydroxypropyl oxyethyl cellulose
- HPMC hydroxypropylmethylcellulose
- MATAC methyl acrylamido propyl triammonium chloride
- Examples include both the Pluronic® polyols having an (P,) a (P 2 ) b (P,) a structure such as Pluronic® F38, L44, P65, F68, F88, L92, P103, P104, P105, F108, L122 and F127, as well as the reverse Pluronic® R series (P 2 ) a (P ] ) b (P 2 ) a structure such as Pluronic® 17R2 and 25R8.
- Other miscellaneous materials include propyleneoxide, urea, triethanolamine, alkylphenol ethoxylates (Iconol series), and linear alcohol alkoxylates (Plurafac series).
- Additives affect the viscosity of the compositions differently depending upon the nature of the additive and its concentration. Some additives will affect the initial or final viscosity, whereas others will affect the temperature range of the viscosity response, or both. Potassium chloride and acetamide MEA are two examples of additives which decrease the final viscosity of the composition (see, Example 32).
- KC1 (0.25%) added to a 1 wt% reversibly gelling polymer composition reduces the viscosity by about 3000 cps. See, Figure 7.
- the humectant, acetamide MEA lowers the viscosity of a 1 wt% solution by approximately 1,500 cps (see, Figure 8).
- Glycerin, ethanol and dimethicone copolymer have been shown to affect the temperature range over which the viscosity response occurs. Glycerin shifts the transition temperature to a slightly lower range from an initial 24-34 °C to about 24- 30 ° C, but does not affect the final viscosity (see, Example 28). The effect of ethanol on the viscosity is different at different concentration levels. At 5 wt% and 10 wt% added ethanol, the transition temperature is shifted to lower ranges, e.g., 24-29 °C and 20-29 °C, respectively. At 20 wt% added ethanol, the composition not only exhibits a lowering of the transition temperature, but also a marked increase in initial and final viscosity. See, Figure 9. Dimethicone copolymer (1 wt%) also changed the transition temperature, but in this instance the transition temperature range was raised to 28- 41 °C. Thus, proper selection of additives permits the formulator to adjust the transition temperature to various ranges.
- the polymer network will have the ability to act as a primary emulsifier without any (or with very little) addition of traditional surfactant.
- the responsive polymer network will also act as a stabilizer for oil-soluble ingredients that would conventionally need to be solubilized by oils in formulation.
- the hydrophobic portion of the polymer network (PPO) forms domains which act as reservoirs for an oil- soluble or hydrophobic additive, such as a hydrophobic pharmaceutical agent, as is illustrated in Figure 11.
- an oil- soluble or hydrophobic additive such as a hydrophobic pharmaceutical agent
- the polymer network may be useful as a solubilization agent in pharmaceutic applications.
- a self-assembling system comprising the reversibly gelling polymer network exhibits thermogelation, pH sensitivity, and the ability to solubilize hydrophobic agents in aqueous media.
- poloxamer is copolymerized with poly(acrylic acid) (PAA) according to the invention
- PAA poly(acrylic acid)
- the resulting copolymer network is bioadhesive and can be applied in a number of therapies.
- the materials described in this invention combine "reverse" thermoviscosification mucoadhesion, solubilization of hydrophobic and difficult to manage moieties, easy formulation, and protection of agents from degradation to provide a superior medium for pharmaceutic and personal care products.
- the polymeric network is capable of solubilizing and releasing bioactive materials. Solubilization is expected to occur as a result of dissolution in the bulk aqueous phase or by incorporation of the solute in micelles created by the hydrophobic domains of the polymeric network. Release of the drug would occur through diffusion or network erosion mechanisms.
- the polymer network compositions of the present invention may be utilized for a wide variety of pharmaceutic applications.
- an effective amount of pharmaceutically active agent(s) which imparts the desirable pharmaceutic effect is incorporated into the reversibly gelling polymer network composition of the present invention.
- the selected agent is water soluble, which will readily lend itself to a homogeneous dispersion through out the reversibly gelling polymer network composition; however, the polymer network has been demonstrated to significantly solubilize or suspend hydrophilic agents in order to improve formulation homogeneity (see, Example 34).
- the agent(s) is nonreactive with the polymer network composition.
- disperse or suspend lipophilic material throughout the polymer network composition.
- Esophageal and buccal applications One indication for the use of this polymeric network would be as a coating to protect tissue from external or internal chemical challenges.
- the polymeric network in the form of an esophageal formulation could coat the esophagus and protect it from the effects of acid, resulting from gastric reflux (GERD).
- GERD gastric reflux
- the neutralized, polyacrylic acid component of the polymeric network could neutralize a certain amount of acid and prevent the acid from acting upon the tissue.
- the polymeric network formulation could include acid absorbing substances, such as, aluminum oxide.
- the polymeric network provides a suitable vehicle for delivering drugs within the esophageal lining. As explained above, its rheological and mucoadhesive properties are desirable attributes for controlling and facilitating drug delivery.
- Opthalmic applications Most ophthalmic drugs are applied to the eye topically to the precorneal area. The most common dosage form is a liquid drop. Drug bioavailability is generally low because liquid formulations are quickly cleared from the eye by tearing and blinking, resulting in the need for frequent dosing and uneven drug delivery.
- the polymeric network provides a new vehicle for achieving greater bioavailability of topically administered ophthalmic drugs.
- Formulations containing it can be applied as drops which viscosify or gel upon contact with eye. Since gelling can be accomplished with low concentrations of the polymer, blurring can be minimized upon drop instillation. Low solid concentrations also help to minimize crusting along the eyelid margins. See, Examples 35-37.
- a particular advantage of the polymeric network is that, as a result of its rheological properties, compositions containing the polymer will evenly coat the precorneal surface. This is in contrast to other ophthalmic drug delivery vehicles which may gel upon application to the eye but which form deposits of the formulation that reside under one eyelid.
- the ability of the polymer to shear-thinning or to evenly spread over the precorneal surface is particularly advantageous in dry eye formulations or in the treatment of inflammation and wound healing conditions.
- polymeric network would be indicated for delivering bioactive materials, such as, anesthetics, mydriatics and cycloplegics, antimicrobial agents (antibacterial, antifungal, antiviral), anti- inflammatory agents, agents for the treatment of glaucoma, ocular decongestants, diagnostic agents, and wound healing agents.
- bioactive materials such as, anesthetics, mydriatics and cycloplegics, antimicrobial agents (antibacterial, antifungal, antiviral), anti- inflammatory agents, agents for the treatment of glaucoma, ocular decongestants, diagnostic agents, and wound healing agents.
- Nasal applications The use of the polymeric network is also indicated for the delivery of drugs to the nasal cavity.
- Nasal drug delivery has been considered as an alternative to parenteral routes of administration of drugs that demonstrate low oral bioavailability.
- efforts have been made to increase the residence time of formulations in the nasal cavity.
- Nasal delivery of drugs can offer advantages over other methods of delivery, including rapid systemic absorption, lower dosing, more rapid onset of desired therapeutic effects, and improved pharmacokinetics.
- it provides an alternative route for administering peptide drugs, which generally have low bioavailability via the oral route and are normally administered parenterally. See, Example 40.
- the rheological properties of the polymeric network are uniquely suited to nasal delivery systems.
- formulation variables can be manipulated to significantly affect the higher temperature viscosity of the polymeric network. These same variables have only minimal effects on the low temperature viscosity. Therefore, formulations containing the polymeric network can be readily sprayed at low temperature; the subsequent viscosification occurs only after administration of the formulation and only at the site of application.
- the polymeric network is also useful for delivering agents such as decongestants, antihistamines, anti-osteoporosis agents, hormones, antineoplastic agents, Parkinsonism drugs, etc..
- agents such as decongestants, antihistamines, anti-osteoporosis agents, hormones, antineoplastic agents, Parkinsonism drugs, etc.
- the polymeric network is also indicated for the application of vaccines, such as those against the influenza virus.
- a further desirable outcome of the use of the polymeric network in the delivery of nasal formulations is the prevention of roll back, or the loss of the formulation by rapid flow to the posterior section of the nasal cavity and into the esophagus.
- roll can lead to unpleasant taste sensations associated with some drug formulations. See, Example 41.
- gelling polymer network of the invention also may be useful in the treatment of not only human conditions but in providing treatments for animal care.
- the polymeric network is indicated for the preparation of topical dermal products, such as antibacterials, antifungals, antipruritics, and antiseborrheia, antiodor, and antiseptic/wound healing preparations.
- Otic products would include ear cleaners with or without actives, such as, antifungals.
- Ophthalmic products would include eye moisturizers or antimicrobial preparations.
- the rheological, solubilizing, drug delivery, and chemical properties provide the formulator of veterinary products the latitude to prepare compositions in a variety of delivery forms and, more importantly, with regard to companion animals, with a non-oily quality. Tablet Excipients. It has been demonstrated that the polymeric network of the invention can be processed by standard pharmaceutical processes, such as lyophilization and air drying. The reversible thermal viscosifying polymer network ma be reconstituted with water, phosphate buffer or calcium chloride solution, without loss or degradation of the rheological properties of the polymer. Thus, it is contemplated that the polymer network of the invention may also be incorporated as excipients into tablets or granules for oral delivery.
- the polymer may be coated on an outer surface of the tablet or may be introduced in powder form into the tablet along with the active agent and other ingredients.
- the poloxamer:poly(acrylic acid) polymer network may be used to promote bioadhesion of the tablet and its contents with the mucosal lining of the gastro-intestinal tract to extend transit time.
- a depot formulation may be prepared and administered at low viscosity to a subdermal or intramuscular site, for example.
- the polymer will viscosify and form a depot site, which will slowly release the active agent.
- the reversible thermally viscosifying polymer network upon contact with body fluids including blood or the like, undergoes gradual release of the dispersed drug for a sustained or extended period (as compared to the release from an isotonic saline solution). This can result in prolonged delivery (over, say 1 to 2,000 hours, preferably 2 to 800 hours) of effective amounts (say, 0.0001 mg/kg/hour to 10 mg/kg/hour) of the drug.
- This dosage form can be administered as is necessary depending on the subject being treated, the severity of the affliction, the judgment of the prescribing physician, and the like.
- the polymeric network may be prepared at higher viscosities in order to suspend micropheres or particles in the formulation.
- the formulation can then take advantage of the shear thinning properties of the polymeric material.
- the formulation is subjected to shear stresses which reduce viscosity and allow an ordinarily viscous formulation to be introduced into the patient by injection. Cessation of the strain results in reestablishing the high viscosity of the formulation, so that the active agent may be slowly released therefrom.
- the variety of different therapeutic agents which can be used in conjunction with the copolymers of the invention is vast.
- therapeutic agents which may be administered via the pharmaceutical compositions of the invention include, without limitation: antiinfectives such as antibiotics and antiviral agents; analgesics and analgesic combinations; anorexics; antihelmintics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiuretic agents; antidiarrheals; antihistamines; antiinflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics, antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations including calcium channel blockers and beta-blockers such as pindolol and antiarrhythmics; antihypertensives; diuretics; vasodilators including general coronary, peripheral and cerebral; central nervous system stimulants; cough and cold preparations, including decongestants; hormones such as estradio
- Suitable pharmaceuticals for parenteral administration are well known as is exemplified by the Handbook on Injectable Drugs, 6th edition, by Lawrence A. Trissel, American Society of Hospital Pharmacists, Bethesda, Md., 1990 (hereby incorporated by reference).
- the polymeric network is effective in extending the duration of contact of preparations that have been applied to mucosal tissues. In providing a longer residence time, the polymeric network provides a valuable tool for increasing drug delivery across mucosal surfaces.
- the polymeric network also may be used for products in which there is no bioactive ingredient.
- the function of the polymeric network would be to provide, for example, a protective or lubricating film to the surface of the tissue.
- the polymeric network could be the basic ingredient for a lubricating drop for the eye. By its nature, that is, that of a hydrogel, it could provide a long lasting lubricious and moisturizing film to the eye of individuals suffering from dry eye conditions due to pathological states or environmental stress. Other similar indications would be for nasal or vaginal moisturizers.
- a sterile environment may be required. It is contemplated as within the scope of the invention that the reversibly gelling polymer network compositions of the present invention may be prepared under sterile conditions. See, Example 16.
- the concentrations of the hormones was determined spectrophotometrically at 240 nm (progesterone) or 280 nm (estradiol).
- the solubility curves as a function of temperature for various concentrations of the polymeric network are shown in Figure 12A (estradiol) and Figure 13A (progesterone).
- the results show that increasing the concentration of the polymeric network increased the solubility of the hormones and that this solubility was greater at higher temperatures.
- the kinetics of the in vitro release of the hormones from the polymeric network are shown in Figures 12B and 13B. These studies were performed using thermostatted, vertical Franz cells. Spunbonded poly(propylene) micro filters (15-20 micron retention) were used to separate the feed and receiving chambers.
- the receiving chamber consisted of 20% polyethylene glycol in water.
- Figure 12B shows that the initial transport rate increases with decreasing concentrations of the polymeric network.
- Figure 13B shows that this initial transport rate also increases with a decrease in the temperature. Both of the these results are related to the changes in the macroviscosity of the compositions.
- the poloxamer:poly(acrylic acid) polymer network has been evaluated under Good Laboratory Practice (GLP) standard protocols known in the art for toxicity in animal models and found to exhibit no toxic effects.
- GLP Good Laboratory Practice
- the results of the toxicity study are summarized in the following Table 1.
- the non-toxicity of the polymer network makes it an ideal candidate for use in pharmaceutic compositions.
- Table 1 Toxicity data for 6% poloxamer: poly(acrylic acid) solution at pH 7.
- Preparation of pharmaceutic compositions may be accomplished with reference to any of the pharmaceutic formulation guidebooks and industry journals which are available in the pharmaceutic industry. These references supply standard formulations which may be modified by the addition or substitution of the reversible viscosifying polymer network of the present invention into the formulation. Suitable guidebooks include Pharmaceutics and Toiletries Magazine, Vol. I l l (March, 1996); Formulary: Ideas for Personal Care; Croda, Inc, Parsippany, NJ (1993); and Pharmaceuticon: Pharmaceutic Formulary. BASF, which are hereby incorporated in their entirety by reference.
- the pharmaceutic composition may be in any form. Suitable forms will be dependant, in part, of the intended mode and location of application.
- Opthalmic and otic formulations are preferably administered in droplet or liquid form; nasal formulations are preferable administered in droplet or spray form, or may be administered as a powder (as a snuff); vaginal and rectal formulations are preferably administered in the form of a cream, jelly or thick liquid; veterinary formulations may be administered as a cream, lotion, spray or mousse (for application to fur or exterior surface); esophageal and buccal oral cavity applications are preferably administered from solution or as a powder; film forming applications or dermal applications may be administered as a lotions, creams, sticks, roll-ons formulations or pad-applied formulations.
- Exemplary drugs or therapeutics delivery systems which may be administered using the aqueous responsive polymer network compositions of the invention include, but are in no way limited to, mucosal therapies, such as esophageal, otic, rectal, buccal, oral, vaginal, and urological applications; topical therapies, such as wound care, skin care and teat dips; and intravenous/subcutaneous therapies, such as intramuscular, intrabone (e.g., joints), spinal and subcutaneous therapies, tissue supplementation, adhesion prevention and parenteral drug delivery.
- further applications include transdermal delivery and the formation of depots of drug following injection. It will be appreciated that the ionic nature of the "structural component" component of the responsive polymer network provides an adhesive interaction with mucosal tissue.
- the reversibly gelling polymer network composition of the present invention is suited for application under a variety of physiological conditions, a wide variety of pharmaceutically active agents may be incorporated into and administered from the polymer network composition.
- the pharmaceutic agent that may be loaded into the polymer networks of the present invention are any substance having biological activity, including proteins, polypeptides, polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, and synthetic and biologically engineered analogs thereof.
- suitable pharmaceutic agents that might be utilized in a delivery application of the invention include literally any hydrophilic or hydrophobic biologically active compound.
- the drug is one that has already been deemed safe and effective for use by the appropriate governmental agency or body.
- Drugs that are not themselves liquid at body temperature can be incorporated into polymers, particularly gels.
- peptides and proteins which may normally be lysed by tissue-activated enzymes such as peptidases, can be passively protected in gels as well. See, Gehrke et al. Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 22:145 (1995).
- Pharmaceutic agents includes pharmacologically active substances that produce a local or systemic effect in animals, plants, or viruses.
- the term thus means any substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease or in the enhancement of desirable physical or mental development and conditions in an animal, plant, or virus.
- the term "animal” used herein is taken to mean mammals, such as primates, including humans, sheep, horses, cattle, pigs, dogs, cats, rats, mice; birds; reptiles; fish; insects; arachnids; protists (e.g. protozoa); and prokaryotic bacteria.
- plant means higher plants (angiosperms, gymnosperms), fungi, and prokaryotic blue-green "algae” ( i.e. cyanobacteria).
- the pharmaceutically active compound may be any substance having biological activity, including proteins, polypeptides, polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, and synthetic and biologically engineered analogs thereof.
- protein is art-recognized and for purposes of this invention also encompasses peptides.
- the proteins or peptides may be any biologically active protein or peptide, naturally occurring or synthetic.
- proteins include antibodies, enzymes, steroids, growth hormone and growth hormone-releasing hormone, gonadotropin-releasing hormone, and its agonist and antagonist analogues, somatostatin and its analogues, gonadotropins such as luteinizing hormone and follicle-stimulating hormone, peptide-T, thyrocalcitonin, parathyroid hormone, glucagon, vasopressin, oxytocin, angiotensin I and II, bradykinin, kallidin, adrenocorticotropic hormone, thyroid stimulating hormone, insulin, glucagon and the numerous analogues and congeners of the foregoing molecules.
- gonadotropins such as luteinizing hormone and follicle-stimulating hormone, peptide-T, thyrocalcitonin, parathyroid hormone, glucagon, vasopressin, oxytocin, angiotensin I and II, bradykinin, kallidin, a
- the pharmaceutical agents may be selected from insulin, antigens selected from the group consisting of MMR (mumps, measles and rubella) vaccine, typhoid vaccine, hepatitis A vaccine, hepatitis B vaccine, herpes simplex virus, bacterial toxoids, cholera toxin B-subunit, influenza vaccine virus, bordetela pertussis virus, vaccinia virus, adenovirus, canary pox, polio vaccine virus, plasmodium falciparum, bacillus calmette geurin (BCG), klebsiella pneumoniae, HIV envelop glycoproteins and cytokins and other agents selected from the group consisting of bovine somatropine (sometimes referred to as BST), estrogens, androgens, insulin growth factors (sometimes referred to as IGF), interleukin-I, interleukin-II and cytokins. Three such cytokins are interferon-.beta., interferon-.gamma. and tuft
- Examples of bacterial toxoids are tetanus, diphtheria, pseudomonas A, mycobacterium tuberculosis.
- Examples of HIV envelop glycoproteins are gp 120 and gp 160 for AIDS vaccines.
- Examples of anti-ulcer H.sub.2 receptor antagonists are ranitidine, cimetidine and famotidine, and other anti-ulcer drugs are omparazide, cesupride and misoprostol.
- An example of a hypoglycaemic agent is glizipide. Insulin is used for the control of diabetes.
- Classes of pharmaceutically active compounds which can be loaded into a reversible thermal viscosifying polymer network composition include, but are not limited to, anti-AIDS substances, anti-cancer substances, antibiotics, immunosuppressants (e.g. cyclosporine) anti-viral substances, enzyme inhibitors, neurotoxins, opioids, hypnotics, antihistamines, lubricants tranquilizers, anti-convulsants, muscle relaxants and anti-Parkinson substances, anti-spasmodics and muscle contractants, miotics and anti-cholinergics, anti-glaucoma compounds, anti- parasite and/or anti-protozoal compounds, anti-hypertensives, analgesics, anti-pyretics and anti-inflammatory agents such as NSAIDs, local anesthetics, ophthalmics, prostaglandins, anti-depressants, anti-psychotic substances, anti-emetics, imaging agents, specific targeting agents, neurotransmitters, proteins, cell response modifiers, and vaccines
- Exemplary pharmaceutical agents considered to be particularly suitable for incorporation into the pharmaceutical composition of the invention with retention of therapeutic effectiveness and other advantageous properties include but are not limited to imidizoles, such as miconazole, econazole, terconazole, saperconazole, itraconazole, metronidazole, fluconazole, ketoconazole, and clotrimazole, luteinizing-hormone- releasing hormone (LHRH) and its analogues, , nonoxynol-9, a GnRH agonist or antagonist, natural or synthetic progestrin , such as selected progesterone, 17- hydroxyprogeterone derivatives such as medroxyprogesterone acetate, and 19- nortestosterone analogues such as norethindrone, natural or synthetic estrogens, conjugated estrogens, estradiol, estropipate, and ethinyl estradiol, bisphosphonates including etidronate, alendronate, tilu
- Effective and efficient delivery involves four primary elements: a method of holding an optimal quantity of peptides against the mucosa for an extended period; a method of controlling the release of the peptides in a desired pattern (e.g., burst, sustained, circadian, etc.), transferring the peptides from the mucosal surface to the blood sera or other target, and maintenance of activity of peptides.
- the measure of merit is the reliable achievement of a desired pharmaceutical effect with minimal wasted active material-for example, the achievement and sustaining of an effective level of active peptide in the blood stream for a given time period with minimal excess delivery and minimal loss of activity through inactivation or erosion.
- the structural component and responsive component of the system can be chosen for protein delivery.
- the structural component can be a mucoadhesive material (acrylic acid).
- the structural component can be a material which erodes (acrylic acid) or one that degrades (hyaluronic acid).
- the backbone can be crosslinked, can involve comonomers, and can be of varying molecular weights or structures. These modifications to the backbone directly effect retention of the Peptide-gel system, patterns of release, and peptide activity.
- additional pharmaceutically acceptable carriers may be included in the composition, such as by way of example only, emollients, surfactants, humectants, powders and other solvents. Preservatives can be desirably incorporated into the pharmaceutic compositions of the invention to protect against the growth of potentially harmful microorganisms.
- Suitable preservatives include, but are not limited to, alkyl esters of para- hydroxybenzoic acid, hydantoin derivatives, parabens, propioniate salts, triclosan tricarbanilide, tea tree oil, alcohols, farnesol, farnesol acetate, hexachlorophene and quaternary ammonium salts, such as benzolconjure, and a variety of zinc and aluminum salts.
- Pharmaceutic chemists are familiar with appropriate preservatives and may selects that which provides the required product stability. Preservatives are preferably employed in amounts ranging from about 0.0001% to 2% by weight of the composition.
- Emollients can be desirably incorporated into the pharmaceutic compositions of the invention to provide lubricity to the formulation.
- Suitable emollients may be in the form of volatile and nonvolatile silicone oil, highly branched hydrocarbons and synthetic esters. Amounts of emollients may be in the range of about 0.1-30 wt%, and preferably about 1-20 wt%>. A variety of oily emollients may be employed in the compositions of this invention.
- emollients may be selected from one or more of the following classes: triglyceride esters; acetoglyceride esters; ethoxylated glycerides; alkyl esters of fatty acids having 10 to 20 carbon atoms; alkenyl esters of fatty acids having 10 to 20 carbon atoms; fatty acids having 10 to 20 carbon atoms; fatty alcohols having 10 to 20 carbon atoms; fatty alcohol ethers, such as ethoxylated fatty alcohols of 10 to 20 carbon atoms having attached thereto from 1 to 50 ethylene oxide groups or 1 to 50 propylene oxide groups; ether-esters such as fatty acid esters of ethoxylated fatty alcohols; lanolin and derivatives; polyhydric alcohol esters; wax esters; beeswax derivatives; vegetable waxes including carnauba and candelilla waxes; phospholipids; sterol including cholesterol and cholesterol fatty acid esters; and amides such as
- Humectants may be added to the composition to increase the effectiveness of the emollient, to reduce scaling, to stimulate removal of built-up scale and improve skin feel.
- the amount of humectant may be in the range of about 0.5-30 wt% and preferably between 1-15 wt%.
- antibiotics and antimicrobials may be included in the composition of the invention.
- Antimicrobial drugs preferred for inclusion in compositions of the present invention include salts of ⁇ -lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, triclosan, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracycline, clindamycin.
- ethambutol hexamidine isethionate, metronidazole, pentamidine, gentamicin, kanamycin, lineomycin, methacycline, methenamine, minocycline, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, miconazole and amanfadine and the like.
- a wide variety of acids, bases, buffers, and sequestrants can be utilized to adjust and/or maintain the pH and ionic strength of the compositions useful in the instant invention.
- Materials useful for adjusting and/or maintaining the pH and/or the ionic strength include sodium carbonate, sodium hydroxide, hydrochloric acid, phosphoric acid, sulfuric acid, acetic acid, sodium acetate, sodium hydrogen phosphate, sodium dihydrogen phosphate, citric acid, sodium citrate, sodium bicarbonate, triethanolamine, EDTA, disodium EDTA, tetrasodium EDTA, and the like.
- a general method of making the responsive polyme ⁇ structural polymer network compositions of the present invention comprises solubilization of the responsive polymer, e.g., poloxamer, in a monomer of the structural polymer, e.g., acrylic acid monomer, followed by polymerization of the monomer.
- Polymerization may be accomplished by addition of a polymerization initiator or by irradiation techniques.
- the initiator may be a free radical initiator, such as chemical free radical initiators and uv or gamma radiation initiators.
- free radical initiators may be used according to the invention, including, but in no way limited to ammonium persulfate, benzoin ethyl ether, benzyl peroxide, l,2'-azobis(2,4- dimethylpentanitrile) (Vazo 52) and azobisisobutyronitrile (AIBN). Initiation may also be accomplished using cationic or ionic initiators. Many variations of this methods will be apparent to one skilled in the art and are contemplated as within the scope of the invention.
- the poloxamer component may be dissolved in an acrylic acid/water mixture instead of pure monomer. It may be desirable to remove unreacted monomer and or free poloxamer from the resultant polymer network. This may be accomplished using conventional techniques, such as, by way of example, dialysis or sohxlet extraction.
- the scheme for bonding of poloxamer to acrylic acid may involve initiation (eq 1), hydrogen abstraction from the propylene or ethylene moiety of the poloxamer (eq 3), and attachment to acrylic acid via addition across the unsaturated bond (eq 10). Propagation (eq 8) leads to the final PAA.
- the mechanism may proceed by initiation according to eqs. (1) and (2), propagation to form PAA (eq.8), a chain transfer reaction to generate a reactive poloxamer moiety (eq. 5), followed by addition of the reactive poloxamer moiety to the unsaturated bond of acrylic acid (eq. 10) and subsequent propagation of the PAA chain.
- the polymer network may include a plurality of poly(acrylic acid)) units bonded to a single poloxamer unit or, alternatively, a plurality of poloxamer units bound to a single PAA backbone. Combinations of these alternatives are also a possibility.
- Reverse phase polymerization may be used to prepare polymer network beads by dispersion of the poloxamer and acrylic acid monomer mixture in a nonpolar solvent such as hexane or heptane.
- the aggregating polymer/monomer solution is dispersed with agitation in the nonpolar solvent in order to suspend droplets of the solution.
- Polymerization of the monomer is initiated by conventional means (i.e., addition of a initiator or irradiation) in order to polymerize the monomer and form responsive polymer network beads. See, U.S.S.N. 08/276,532 filed July 18, 1995 and entitled “Useful Responsive Polymer Gel Beads" for further information on the preparation of polymer gel beads, herein incorporated by reference.
- Such a method may be particularly desirable to provide a heat sink for the heat generated in the exothermic polymerization reaction.
- polymer network complexes and aqueous gelling solutions of the present invention may be understood with reference to the following examples, which are provided for the purposes of illustration and which are in no way limiting of the invention.
- Example 1 This example describes the synthesis of a polymer network and an aqueous responsive polymer network solution prepared using a triblock polymer of poly(ethyleneoxide) and poly(propyleneoxide), Pluronic® F27 polyol, and poly(acrylic acid). This example also characterizes the gelation and the physical properties of the resultant polymer network.
- Viscosity measurements A known amount of the resultant polymer was suspended in 100 ml deionized water into which NaOH was added. Following swelling for 3 days while stirring, the pH of the resulting fine suspension was adjusted to 7. Samples of 15 ml each were taken, and pH in each vial was adjusted to desired value by addition of 1 M HC1 or NaOH. Samples were then kept overnight and their viscosities were measured at different temperatures using Brookfield viscometer using either an SC4-18 or an SC4-25 spindle.
- Example 2 This example describes a standard operating procedure for the manufacture of the reversible gelling polymer network.
- a NaOH solution was prepared by dissolving 131.8 g NaOH pellets in 131.8 mL DI water (50% solution). The NaOH was allowed to dissolve completely. The NaOH solution will be used to convert a percentage of the acrylic acid to sodium acrylate in situ.
- Acrylic acid monomer 4 kg is charged into a monomer feed tank and agitated at 250 rpm. NaOH is added slowly. The precipitate formed as the acrylic acid is neutralized to sodium acrylate is allowed to dissolve.
- Pluronic® F127 (3.5 kg) is slowly added to the monomer feed tank. Pluronic® F127 is dissolved under continued agitation.
- Norpar 12 (a refined C-12 alkane) is added to the reaction vessel (37 L). The mixture is agitated at 100 rpm. Stabilizer solution of Ganex V-126 is prepared in 2L Norpar 12 and added to the reactor under agitation.
- a reaction vessel was degassed using a nitrogen sparge introduced from the bottom of reactor and was continued throughout the reaction.
- Initiator 13.63 g Lauryl peroxide and 4.23 g Vazo 52 in 0.7 kg acrylic acid monomer
- the monomer solution was transferred to the reaction vessel. Agitation was increased to 150 rpm.
- Nitrogen sparging continued for an additional 20 minutes and then heating began. Heating began at a rate of 0.5-1.0 °C/min up to 75 °C.
- the reaction began to exotherm at about 45-50 °C and is allowed to continue without cooling until a maximum is reached. It is then cooled to 75 °C using forced cooling.
- the reaction continued for 12 hours and was then cooled to 35 °C.
- the slurry was transferred into pails and the polymer beads were allowed to settle.
- the slurry was filtered through Buchner Funnels with filter paper (11 ⁇ m pore size) until the bulk of the Norpar had been removed from the beads.
- the beads were washed three times with heptane.
- the filtered beads were transferred to a Pyrex drying tray and spread on the tray in a uniform layer.
- the beads were dried under vacuum for 4 hours at 40-50 °C.
- the dried beads were analyzed as follows.
- Elemental analysis The elemental analysis was performed by Quantitative Technologies, Inc., Whitehouse, NJ using a Perkin Elmer 2400 CHN Elemental Analyzer. Analysis provided C (52.49%), H (7.50%), N ( ⁇ 0.05%), the balance assumed to be oxygen (39.96%).
- TGA Thermal Gravimetric Analysis
- the effect of both the bonded and non-bonded poloxamer on the gelation properties of the responsive polymer network has been determined by extraction of the non-bonded poloxamer from the material. Such extraction studies have established that the graft co-polymer alone exhibits the characteristic reverse thermal gelation of the composition; however, the presence of non-bonded poloxamer component modulates the gelation process.
- the non-bonded poloxamer component can affect the temperature of transition (from liquid to gel) and the degree of transition and assists in a more controlled and reproducible transition.
- Bound poloxamer determination bv ethylene oxide (EQ-) titration was performed as follows. A 5 gm sample of the product polymer was extracted in dichloroethane for three hours at reflux temperatures. The solid is removed and dried under a vacuum for 12 hours at room temperature. The dry material is then analyzed using ASTM method D 2959-95, "Standard Test Method for Ethylene Oxide Content". The amount of EO in the sample is related to the amount of poloxamer bound to the polymer. The typical result is approximately 15 % by weight of EO.
- the relative amount of free poloxamer may be varied dependent upon the relative proportions of starting materials and the method of polymerization. Although the residual solids presumably contain only poloxamer which is bonded to the poly(acrylic acid), i.e. , a graft co-polymer, the material still shows strong viscosification when it is neutralized and dissolved in water. However, the temperature of viscosification is increased substantially and the degree of viscosification per gram of total solids is increased by removal of free poloxamer. Thus, the free poloxamer plays a role in modifying the extent and temperature of viscosification. The poloxamer undergoes conformational changes and changes to the critical micelle concentration as a function of temperature.
- the poloxamer will change from an open, non-aggregated form to a micellular, aggregated form with changes in temperature.
- Residual acrylic monomer determination bv gas chromato raph v (GC).
- the residual acrylic acid monomer was determined by GC analysis using a Hewlet Packard GC 5890A, using a HP-FFDAP-TPA 10 m x 0.53 mm x l ⁇ m column. The sample was extracted and run in methanol. Using an internal standard ratio, the sample was compared to a one point calibration. The typical results for this assay were below 70 ppm acrylic acid monomer.
- Residual Norpar solvent bv GC Residual Norpar solvent bv GC.
- the residual Norpar in the sample was determined by GC using the above method and comparing the Norpar peaks to that of a standard. The typical results were below 1.5 wt%.
- UV-vis spectrum Optical clarity data of UV-vis spectrophotometer was obtained. A 1.0% solution in water was prepared and measured at 420 nm. Transmittance (%) was typically greater than 90%.
- Differential scanning calorimetrv fDSQ The DSC was performed by Massachusetts Material Research, Inc., West Boylston, MA using a temperature ramp from 30 to 350 °C at 5 °C/min. The resolution for the system was set to 4 (1.0°C/min for all slope changes). The assay yielded one endothermic event at 265 °C, typically 270 J/g.
- Example 10 This example describes the synthesis of a responsive polymer network gel composition prepared using Pluronic ® F127 and a copolymer of methacrylic and acrylic acid.
- Methacrylic acid (Aldrich, 0.2 g) and acrylic acid (Aldrich, 1.8 g) were mixed and used to dissolve 2.0 g Pluronic ® F127.
- the solution was dearated for 0.5 h and, following addition of 100 :1 freshly prepared saturated solution of ammonium persulfate in deionized water, was kept at 70 °C for 16 h resulting in a transparent polymer.
- a sample of the polymer was suspended in deionized water with added NaOH. Following swelling for three day, pH was adjusted to 9.0.
- a 2 wt% composition viscosified at temperatures of 40 °C and higher. Viscosity vs. temperature profile is shown in Figure 18.
- Example 11 The following example demonstrates the effect of hydrophilic/hydrophobic ratio on the gelling temperature.
- Polymer network compositions were prepared from the following poloxamers shown in Table 3. Table 3. Composition of poloxamers investigated.
- the poloxamer (3.0 g) was dissolved in 3.0 g acrylic acid. The solution was deaerated by N 2 bubbling for 20 min. and following addition of the 100 :1 of freshly prepared saturated solution of ammonium persulfate in deionized water was kept at 70 °C for 16 h resulting in a strong whitish polymer. A sample of the polymer obtained (0.4 g) was suspended in 40 ml deionized water into which NaOH was added. Suspended responsive polymer network particles were allowed to dissolve under constant stirring. The resulting 1 wt% polymer network solutions were subjected to the viscosity measurement at shear rate of 132 or 13.2 sec "1 using a SC4- 18 spindle.
- Example 12 The aim of this example is three-fold: ( i ) to demonstrate responsive polymer network compositions using a responsive component other than triblock polyoxyalkylene copolymers, (ii) to preserve useful properties of responsive polymer network, namely, ease of synthesis, viscosifying at body temperature, bioadhesiveness, and entirely benign components, and (iii) to incorporate drug into the responsive polymer network composition.
- a responsive component other than triblock polyoxyalkylene copolymers e.glycol
- Nonoxynol 9, drug name is Igepal CO-630 e.glycol
- This remarkable compound is surface active, possesses cloud point at around 55 °C and is used as a spermicide and anti-HIV agent in vaginal applications. Synthesis and properties of the resulted responsive polymer network are described below.
- Viscosity measurement Viscosity vs temperature effect for responsive polymer network made of Nonoxanol 9 and polyacrylic acid (1: 1) in deionized water (pH 7) is presented in Figure 20.
- the viscosity is measured at shear rate of 2.64 sec-1 using a SC4-18 spindle which allows a very sensitive measurement. It can be seen that the responsive polymer network starts to viscosify at about 30 °C and the viscosity approaches maximum at 55 °C at which point aggregates are formed (cloudiness is developed) and the viscosity drops precipitously.
- Example 13 The following example is related to release of an active agent from a poloxamer:poly(acrylic acid) polymer network. Drug loading and kinetics of release of the protein hemoglobin from poloxamer:poly(acrylic acid) polymer network is described.
- Pluronic ® F127 (3.0 g) was dissolved in 3.0 g acrylic acid. The solution was deaerated by N 2 bubbling for 0.5 h and following addition of 100 FI of freshly prepared saturated solution of ammonium persulfate (Kodak) in deionized water was kept at 70° C for 16 h resulting in a transparent polymer. The resultant responsive polymer network obtained (5 g) was suspended in 95 ml deionized water into which NaOH was added. The resulting suspension was allowed to swell for 7 days.
- a 5 wt% responsive polymer network composition (3 g) was allowed to swell for 16 h in 10 ml of 0.25 mg/ml solution of human hemoglobin (Sigma) in deionized water adjusted to pH 8. The resulting mixture was well shaken and placed into the feed chambers of customized vertical, static, Franz-like diffusion cells made of Teflon. The feed and receiver chambers of the diffusion cells were separated by mesh screens (# 2063). The receiver chamber was continuously stirred by a magnetic bar. The cells were allowed to equilibrate to either 25 or 37°C (in an oven).
- the feed and receiver phases consisted of 1 g of the hemoglobin-loaded responsive polymer network and 6 ml of phosphate-buffered saline (pH 7.4), respectively.
- the feed phase was made of 1 g of 0.25 mg/ml hemoglobin solution.
- the kinetic time commenced.
- Samples of the receiver phase was withdrawn from time to time and their absorbance was measured spectrophotometrically at 400 nm.
- corresponding calibration curves (absorbance in PBS versus hemoglobin concentration) were generated. The results of the kinetic experiment are presented in Figure 21.
- Example 14 The following example is related to release of an active agent from a poloxamer: poly (aery lie acid) polymer network. Drug loading and kinetics of release of the protein lysozyme from a polymer network is reported. Lysozyme loading and release.
- a 5 wt% responsive polymer network composition (3 g) was allowed to swell for 16 h in 10 ml of 1 mg/ml solution of chicken egg-white lysozyme (Sigma) and 1.5 mg/ml sodium dodecyl sulfate (Aldrich) in deionized water adjusted to pH 8.5. The resulting mixture was well shaken and placed into the feed chambers of customized vertical, static, Franz-like diffusion cells made of Teflon.
- the feed and receiver chambers of the diffusion cells were separated by mesh screens (# 2063).
- the receiver chamber was continuously stirred by a magnetic bar.
- the cells were allowed to equilibrate to either 25 or 37 °C (in an oven).
- the feed and receiver phases consisted of 1 g of the lysozyme-loaded responsive polymer network and 6 ml of phosphate-buffered saline (pH 7.4), respectively.
- the feed phase was made of 1 g of 1 mg/ml lysozyme solution. After the feed solution had been loaded into the cell, the kinetic time commenced. Samples were withdrawn and their absorbance measured spectrophotometrically at 280 nm.
- a calibration curve was prepared for lysozyme concentration ranging from 0 mg/ml to 0.5 mg/ml in phosphate buffered saline.
- the results of the kinetic experiment are presented in Figure 22. It can be seen that the rate of lysozyme release from the responsive polymer network composition was substantially lowered at 37°C when compared to that at 25 °C, because of viscosity increase in responsive polymer network at elevated temperatures (see Figure 2).
- Example 15 The following example is related to release of an active agent from a poloxamer:poly(acrylic acid) polymer network. Drug loading and kinetics of release of insulin from a responsive polymer network composition is reported.
- a 5 wt% responsive polymer network composition (3 g) was allowed to swell for 16 h in 10 ml of 5 mg/ml solution of bovine Zn 2+ -insulin (Sigma) in deionized water adjusted to pH 7.
- the resulting mixture was well shaken and placed into the feed chambers of customized vertical, static, Franz-like diffusion cells made of Teflon.
- the feed and receiver chambers of the diffusion cells were separated by mesh screens (# 2063).
- the receiver chamber was continuously stirred by a magnetic bar.
- the cells were allowed to equilibrate to either 25 or 37 °C (in an oven).
- the feed and receiver phases consisted of 1 g of the insulin-loaded responsive polymer network and 6 ml of phosphate-buffered saline (pH 7.4), respectively.
- the feed phase was made of 1 g of 5 mg/ml insulin solution. After the feed solution had been loaded into the cell, the timing commenced. Samples were withdrawn and their absorbance was measured spectrophotometrically at 280 nm. A calibration curve was prepared for insulin concentration ranging from 0 mg/ml to 1.25 mg/ml in phosphate buffered saline. The results of the kinetic experiment are presented in Figure 23.
- Example 16 This example demonstrates the preparation of a sterile reversibly gelling polymer network aqueous composition and the stability of the composition to sterilization.
- the polymer network is prepared as described in Example 1, except that the composition is prepared at 2 wt% Pluronic ® F127 polyol/poly(acrylic acid). After dissolution of the 2 wt% polymer network in water, the viscosity is measured. The composition then is sterilized by autoclaving at 121 °C, 16 psi for 30 minutes. Viscosity is determined after sterilization.
- Example 33 This example demonstrates the preparation of pharmaceutic compositions of formulations tailored to particular applications.
- Formulations including a nonionic surfactant formulation An O/W (oil-in- water) emulsion was made by combining the following ingredients utilizing conventional mixing techniques:
- Formulations including a cationic surfactant formulation An O/W (oil-in- water) emulsion was made by combining the following ingredients utilizing conventional mixing techniques:
- Formulations including an anionic surfactant formulation An O/W (oil-in- water) emulsion was made by combining the following ingredients utilizing conventional mixing techniques:
- ro a os ava a e rom ro a
- water is added to 100% w/w and allowed to mix to homogeneity.
- This formulation contains a anionic surfactant and gives an emulsion that is fluid at room temperature but viscosifies above 32 °C.
- Vaginal Moisturizer An oil-free, lubricous, vaginal moisturizer is made by combining the following ingredients utilizing conventional mixing techniques:
- the composition displays a flowable creamy lotion appearance with excellent moisturizing, emolliency, spreadability and absorption characteristics at room temperature, and after heating the formulation to 32°C, the composition thickens to a gel-like consistency.
- the composition displays a flowable jelly appearance with excellent spreadability and absorption characteristics at room temperature, and after heating the formulation to 32 °C, the composition thickens to a gel-like consistency.
- the composition displays a flowable jelly appearance with excellent spreadability and absorption characteristics at room temperature, and after heating the formulation to 32°C, the composition thickens to a gel-like consistency.
- Topical Hormone Delivery Formulation An oil-free, spreadable, topical hormone treatment using estradiol as the hormone is made by combining the following ingredients utilizing conventional mixing techniques:
- the composition displays a flowable jelly appearance with excellent spreadability and absorption characteristics at room temperature, and after heating the formulation to 32°C, the composition thickens to a gel-like consistency.
- Opthalmic Formulation A bioadhesive eye drop formulation is made by combining the following ingredients utilizing conventional mixing techniques:
- Chloride was added. This material was allowed to mix until dissolved. The formula amount of sodium citrate was then added and allowed to dissolve. This was followed by the addition of the formula amount of Pluronic ® F127. This was then allowed to dissolve and the formula amount of responsive polymer composition was then added with moderate to vigorous mixing.
- Example 34 Solubilization studies of model hydrophobic pharmaceutical agents in the poloxamer: polyfacrylic acid) polvmer network: estradiol and progesterone. This example is presented to demonstrate the solubilization and delivery of a hydrophobic bioactive material in the polymeric network. Progesterone and estradiol were used as the hydrophobic agents. Acrylic acid (99%), fluorescein (98%), /3-estradiol (98%), and progesterone
- the microscopic light scattering of 21 nm poly(styrene) latex particles in deionized water and 1 w% reversibly gelling polymer network was measured using He-Ne laser as described previously (See, Matsuo, E.S. , Orkisz, M. , Sun, S.-T. , Li, Y., Tanaka, T. ,
- Solubilization was found to be spontaneous at all temperatures, and the solubilization was endothermic, similar to the solubilization of estriol, as well as indomethacin, by the poloxamer. Notably, ⁇ S of solubilization was always positive, suggesting that the more ordered water molecules surrounding hydrophobic estradiol molecules moved to the less ordered bulk phase when the estradiol was transferred to the hydrophobic core of PPO segments in responsive polymer network.
- the aggregation of the PPO segments at elevated temperatures provides not only temporary cross-linking in the gel, but also a thermodynamically "friendly" environment for the hydrophobic drugs. A similar trend is indicated by the lowering the onset of gelation of the responsive polymer network upon solubilization of fluorescein (Log P 2.1) ( Figure 25).
- Figure 27 shows that the relative amount of progesterone penetrating into the receiver phase decreased 4-fold with the increase of total polymer concentration (bar graph A), whereas the total relative amount of progesterone stayed almost constant as total polymer concentration in the responsive polymer network increased (bar graph B).
- This result shows the existence of two routes of transport of hydrophobic drugs in our model system. Firstly, the drug incorporated into aggregates within the reversibly polymer network system can flow through the membrane along with the erosion of the polymer network; secondly, the drug not associated with the reversibly gelling polymer network aggregates can diffuse out of the polymer network in the feed phase. The second process should not be related to the viscosity of the reversibly gelling polymer network.
- Example 35 This example demonstrates delivery the ability of a poloxamer:poly(acrylic acid) polymeric network in retaining a liquid formulation in the precorneal area of the eye.
- the delivery of drug across the tissues of the front surface of the eye is hindered by the protective mechanisms of tearing, eyelid blinking, and the epithelial barrier. Normal aqueous compositions that are applied to the high are cleared within minutes.
- the following example illustrates the retention time of pharmaceutical agents applied to the eye using the pharmaceutical composition of the invention.
- Example 36 This experiment reports the result of gamma scintigraphy employed as a non-invasive means of monitoring the residence time of the opthalmic compositions of the invention in the rabbit cornea.
- a two-way cross over study was carried out on six New Zealand White rabbits comparing a poloxamer: poly (aery lie acid) polymer network with a control saline solution.
- the hydrogel formulation was radiolabelled by the inclusion of 25 ⁇ l 99m Tc- DTPA to give an activity of 3MBq per dose (20 ⁇ l).
- the saline solution was similarly labeled.
- the dose was delivered directly onto the cornea using a positive displacement pipette and the animal was immediately positioned for imaging. Scintigraphic imaging was carried out using an IGE maxicamera II with a pin-hole collimator.
- Imaging for the hydrogel included a dynamic acquisition for 15 minutes (60 frames at lOsec/frame and 10 frames at 30 sec/frame) followed by two static images at 30 and 60 minutes.
- the saline was imaged dynamically for only 10 minutes (60 frames at lOsec/frame).
- Gelation of the hydrogel on the corneal surface occurred immediately and could be visually observed.
- Dramatically increased retention time was observed with the poloxamer:poly(acrylic acid) polymer composition between the two formulations, as is illustrated in Figure 29.
- Saline clearance half-time was 45 seconds, as compared to 1150 seconds for the poloxamer:poly(acrylic acid) polymer composition.
- Figure 29 includes comparison of clearance half-times for other commercially available materials, which have been evaluated using the identical technique (J.L.
- Example 37 The following example reports on the results on the bioavailability of the mydriatic drug, tropicamide, in the eye.
- a 0.1 % solution of tropicamide was prepared in a 0.1 % solution of the polymeric network; a similar concentration of the drug in saline was used as the control.
- Fifty microliters of each solution was applied to the precorneal area a rabbit.
- the pupillary diameter change was measured with a micrometer at predetermined intervals post-instillation.
- the calculated parameters of the response are presented in Table 16. These results indicate that the polymeric network formulation of tropicamide increased the area under the curve for the mydriatic response as compared to saline. It also prolonged the duration and increased in the intensity of the response. Table 16.
- polymeric network is useful in delivering drugs to the eye by topically administering a formulation of the drug with the polymeric network to the precorneal area. It demonstrates significant improved performance over control saline solution and also other commerically available polymeric vehicles.
- Example 38 In the following example, the clearance of the reversibly gelling polymeric network from the nasal cavity has been monitored using gamma scintigraphy, as described in Example 36.
- a 5 mL sample of the formulation shown in Table 17 was mixed with 3mbq 99m-Tc-DTPA and mixed thoroughly.
- the formulation was loaded into a spray device for nasal administration of ca. 200 ⁇ L doses to each individual.
- the study was performed on two healthy males on two occasions.
- the radiolabeled formulation was administered to one nostril of each subject using the spray device. Scintigraphy images of thirty second duration were taken periodically following administration of the formulation.
- the polymeric formulation was deposited anteriorly in each subject. The averaged data that was corrected for background and isotope decay is presented in Figure 30. Table 17.
- the formulation was cleared via the esophageal and gastrointestinal tract and it did not prove irritating to the nose.
- the nasal formulation of the invention exhibited a t 1/2 of 96 minutes, which compares favorably with conventional polymeric vehicles such as methylcellulose (40- 70 minutes; J. Pharm. Sci. 77(5):405 (1988)) and hydroxypropylcellulose (60-140 minutes; Inter. J. Pharm.43:221 (1988)).
- conventional polymeric vehicles such as methylcellulose (40- 70 minutes; J. Pharm. Sci. 77(5):405 (1988)) and hydroxypropylcellulose (60-140 minutes; Inter. J. Pharm.43:221 (1988)
- the cellulose-based vehicles exhibited a considerably higher initial viscosity, making them unsuitable for spray application.
- the poloxamer:poly(acrylic acid) polymeric vehicle while demonstrating sufficient viscosity and bioadhesiveness after application, was of low initial viscosity and could be easily applied by spray.
- Example 39 In the following example, the clearance of the reversibly gelling polymeric network from the nasal cavity has
- a 3.3 ⁇ L dose of a 0.3 % fluorescein solution in a 0.75 wt% and a 1.5 wt% poloxamer:poly(acrylic acid) polymeric network was introduced into rat nasal passages.
- the clearance of the formulation from the nose was determined by spectrofluorometry.
- the fluorescein concentration in the plasma was determined by high pressure liquid chromatography.
- An intravenous treatment of fluorescein was used as the control.
- the clearance rate and bioavailability a function of time, post instillation, are shown in Table 18.
- results indicate a high level of availability of fluorescein using nasal delivery.
- results also indicate the effect of poloxamer:poly(acrylic acid) polymer concentration on the effectiveness of the nasal formulation.
- concentration levels of polymer increase the clearance time from the application site and the bioavailability of the active agent to the host.
- Yet other parameters may be considered, such as ease of administration, spraying, etc. , which will be apparent to those skilled in the art.
- Example 40 The following example demonstrates the ability of the polymeric network to delivery peptides via the nasal route.
- the measured serum concentrations of LH are presented in Figure 31.
- the maximum concentration of the LH was approximately 40 ng/mL, and the maximum response was observed approximately 3 hours post-administration.
- These results demonstrate that the polymeric network was an effective vehicle for delivering a peptide across the nasal mucosa as evidenced by the stimulated release of luteinizing hormone.
- These results indicate the utility of the polymeric network in delivering bioactive materials for local and systemic effects via the nasal route. Its usefulness in delivering peptides across the nasal mucosa overcomes the significant disadvantages of oral delivery of such macromolecular materials. It further circumvents the less consumer friendly route of parenteral administration.
- Example 41 The ability of the polymeric network to retain the formulation at the site of application and to prevent roll back in nasal passages is illustrated in human volunteers.
- a blind double crossover study was performed on five human volunteers.
- a nasal formulation was prepared using a 0.8 wt% poloxamer:poly(acrylic acid) and 0.025 wt% oxymetalzoline.
- a 3 wt% PVP K-29 with 5% PEG 1450, commercially available as Afrin ® nasal spray (Schering Plough) was used as a comparison nasal formulation.
- a 150 ⁇ l dose of each formulation was administered to the volunteers.
- Example 42 This example demonstrates the ability of the polymeric network to control the transit of formulations through luminal tissues. For example, there is great interest in controlling the release of drugs, i.e. , with regard to location of release, as a formulation passes through the gastrointestinal tract. The two previous residence time studies show the ability of the polymeric network to hold the formulation at the site of immediate application. The following example, on the other hand, shows the passage and clearance of a volume of liquid that contains the polymeric network and that has been taken internally via the oral route.
- the formulation in Table 17 was once again radiolabeled with the 99m- Technitium(Tc)- DTP A complex.
- a 5 mL aliquot of the formulation was administered orally via a syringe to three healthy male subjects at two occasions.
- the presence of the radioactive label in the esophagus was monitored by scintigraphy.
- the amount of the formulation that was retained in the esophagus as a function of time is presented in Figure 32.
- About 65% of the formulation passed into the stomach within 5 seconds, which is about the time that it takes for a solid control to clear through the esophagus. However, up to 15 % of the formulation was retained in the esophagus for 10 minutes.
- the polymeric formulation coated the lower third of the esophagus. This is compared to a sucralfate suspension (a pharmaceutical agent having pepsin-binding and antacid effects), which had a total retention time of 1-2 minutes.
- Example 43 This example demonstrates the utility of the polymeric network in delivering medicaments and drugs to and across mucosal tissue.
- the example demonstrates vaginal delivery of a steroid hormone.
- test formulations were a 5.5% polymeric network solution containing 60 ug estradiol in a 5 mL dose, American Home Products' Premarin vaginal suppository, containing 300 ug of estrogen conjugates, and Bristol Myers Squibb 's Estrace vaginal cream, containing 300 ug of estradiol.
- the formulations were administered to five sheep in a double crossover experiment, and the estradiol blood levels were determined by radioimmunoassay.
- the blood levels of estradiol, following the administration of the test formulations, are presented in Figure 33.
- Example 44 Since new ways are needed for delivering peptides and proteins across mucosal surfaces, the value of the polymeric network in creating compositions that promote such transport is further illustrated in the following example of the vaginal delivery of gonadotropin releasing hormone (GnRH) and analogs of it.
- GnRH gonadotropin releasing hormone
- GnRH, lupron, and deslorelin were mixed into 5.5% polymeric network solutions at concentrations ranging between 20 and 33 ug/mL. Sheep were treated with an amount equivalent to 100 ug of peptide. The bioavailability of the peptides was measured by monitoring the concentrations of circulating luteinizing hormone (LH). The LH levels in untreated sheep served as the control.
- LH circulating luteinizing hormone
- Example 34 The concentrations of LH following administration of the test formulations are presented in Figure 34. Each formulation caused an increase in the LH levels, with the most significant increases arising from the administration of deslorelin. Both deslorelin and lupron provided increases in the LH levels that persisted at least eight hours . These results demonstrate that the polymeric network is effective in delivering peptides across the vaginal mucosa.
- Example 36 demonstrated the ability of the polymeric network to solubilize hydrophobic materials. That example, in conjunction with the vaginal delivery of estradiol (Example 43), demonstrate the value of the polymeric network in formulating and delivering more hydrophobic substances.
- Examples 43 and 44 further demonstrate the ability of the polymeric network to formulate and delivery materials with a wide range of molecular characteristics, such as hydrophobicity-hydrophilicity and molecular weight.
Abstract
Une composition pharmaceutique inclut un véhicule pharmaceutiquement acceptable comprenant un réticulat polymérique capable de gélification thermique réversible. Le réticulat polymérique inclut au minimum un composant de polymère sensible, ledit composant de polymère sensible pouvant s'agréger dans une solution en réponse à une stimulation, et au minimum un composant structurel, ledit composant structurel manifestant des interactions d'auto-répulsion dans des conditions d'utilisation. Le composant sensible est fixé de manière aléatoire audit composant structurel et le réticulat polymérique se caractérise par le fait qu'il se transforme en gel en réponse à ladite stimulation environnementale. La composition comprend en outre un agent pharmaceutiquement actif qui produit un effet pharmaceutique, ledit véhicule et ledit agent étant disposés à l'intérieur d'un milieu aqueux. La composition peut être utilisée pour administrer l'agent pharmaceutique à travers des membranes cutanées, otiques, rectales, vaginales, ophtalmiques, oesophagiennes ou pituitaires.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10509898A JP2000516614A (ja) | 1996-08-12 | 1997-08-12 | 製薬適用用組成物 |
EP97937165A EP0920338A2 (fr) | 1996-08-12 | 1997-08-12 | Composition destinee a des applications pharmaceutiques |
CA002263411A CA2263411A1 (fr) | 1996-08-12 | 1997-08-12 | Composition destinee a des applications pharmaceutiques |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2399696P | 1996-08-12 | 1996-08-12 | |
US2597496P | 1996-09-16 | 1996-09-16 | |
US2818396P | 1996-10-15 | 1996-10-15 | |
US3079896P | 1996-11-14 | 1996-11-14 | |
US3445497P | 1997-01-02 | 1997-01-02 | |
US3417497P | 1997-01-02 | 1997-01-02 | |
US60/034,454 | 1997-01-02 | ||
US60/034,174 | 1997-01-02 | ||
US60/028,183 | 1997-01-02 | ||
US60/023,996 | 1997-01-02 | ||
US60/025,974 | 1997-01-02 | ||
US60/030,798 | 1997-01-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998006438A2 WO1998006438A2 (fr) | 1998-02-19 |
WO1998006438A3 WO1998006438A3 (fr) | 1998-06-25 |
WO1998006438A9 true WO1998006438A9 (fr) | 1998-07-23 |
Family
ID=27556028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/013988 WO1998006438A2 (fr) | 1996-08-12 | 1997-08-12 | Composition destinee a des applications pharmaceutiques |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0920338A2 (fr) |
JP (1) | JP2000516614A (fr) |
CA (1) | CA2263411A1 (fr) |
WO (1) | WO1998006438A2 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6316011B1 (en) * | 1998-08-04 | 2001-11-13 | Madash, Llc | End modified thermal responsive hydrogels |
ATE281475T1 (de) * | 1998-12-14 | 2004-11-15 | Rhodia | Polymere mit thermoverdickungs-eigenschaften und verfahren zu deren herstellung |
EP1315672A4 (fr) | 2000-06-22 | 2006-04-26 | Rxkinetix Inc | Composition de vecteur d'administration et procede pour l'administration d'antigenes et d'autres medicaments |
DE10031741A1 (de) * | 2000-06-29 | 2002-01-17 | Sanguibio Tech Ag | Einen Sauerstoffträger, ausgewählt aus Hämoglobin oder Hämoglobin- und Myoglobin-enthaltende Zubereitung als Externum zur natürlichen Regeneration der Haut bei Sauerstoff-Mangel |
US7138133B2 (en) | 2001-10-10 | 2006-11-21 | The Procter & Gamble Company | Orally administered liquid compositions |
EP1446103B1 (fr) * | 2001-10-19 | 2015-12-23 | Idexx Laboratories, Inc. | Compositions injectables permettant une administration controlee d'un compose pharmacologiquement actif |
FR2833268B1 (fr) * | 2001-12-12 | 2005-07-08 | Fabre Pierre Dermo Cosmetique | Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation |
US7273891B1 (en) | 2002-01-17 | 2007-09-25 | B L Partnership | Stable copolymers |
AU2003225516A1 (en) * | 2002-03-26 | 2003-10-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Responsive biomedical composites |
DE10360847A1 (de) * | 2003-12-20 | 2005-07-28 | Cord Contract Research And Development Gmbh | Medizinisches Gleitgel |
US20070048288A1 (en) * | 2005-08-30 | 2007-03-01 | Lyu Suping | Shear thinning polymer cell delivery compositions |
US20070077302A1 (en) * | 2005-09-30 | 2007-04-05 | Azaam Alli | Methods for stabilizing ophthalmic compositions |
CA2635603C (fr) | 2005-11-30 | 2016-01-19 | Endo Pharmaceuticals Inc. | Traitement de la xerostomie |
GB0704709D0 (en) | 2007-03-12 | 2007-04-18 | Croda Singapore P L | Dispersion, gel and emulsification system |
FR2932070B1 (fr) | 2008-06-10 | 2012-08-17 | Oreal | Ensemble de maquillage et/ou de soin des cils |
FR2940761B1 (fr) | 2009-01-07 | 2012-12-28 | Polymerexpert Sa | Composition anti-ronflement contenant un polymere thermogelifiant |
US10413496B2 (en) | 2012-10-15 | 2019-09-17 | L'oreal | Aqueous wax dispersions |
US10626294B2 (en) | 2012-10-15 | 2020-04-21 | L'oreal | Aqueous wax dispersions containing volatile solvents |
US9408785B2 (en) | 2012-10-15 | 2016-08-09 | L'oreal | Hair styling compositions containing aqueous wax dispersions |
US10561596B2 (en) | 2014-04-11 | 2020-02-18 | L'oreal | Compositions and dispersions containing particles comprising a polymer |
FR3091996B1 (fr) | 2019-01-24 | 2021-01-29 | Les Laboratoires Brothier | Composition cicatrisante |
CN115400219A (zh) * | 2021-05-26 | 2022-11-29 | 弘展生技股份有限公司 | 用于预防组织沾粘的温度敏感组成物及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252318A (en) * | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
EP0832151A2 (fr) * | 1995-06-16 | 1998-04-01 | Gel Sciences, Inc. | Reticulats polymeriques sensibles et leurs procedes d'utilisation |
-
1997
- 1997-08-12 EP EP97937165A patent/EP0920338A2/fr not_active Withdrawn
- 1997-08-12 WO PCT/US1997/013988 patent/WO1998006438A2/fr not_active Application Discontinuation
- 1997-08-12 JP JP10509898A patent/JP2000516614A/ja active Pending
- 1997-08-12 CA CA002263411A patent/CA2263411A1/fr not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6316011B1 (en) | End modified thermal responsive hydrogels | |
WO1998006438A9 (fr) | Composition destinee a des applications pharmaceutiques | |
EP0920338A2 (fr) | Composition destinee a des applications pharmaceutiques | |
AU762677B2 (en) | Prolonged release bioadhesive vaginal gel dosage form | |
US5102666A (en) | Calcium polycarbophil controlled release composition and method | |
US5989535A (en) | Polymeric bioadhesive emulsions and suspensions and methods of treatment | |
JP3181912B2 (ja) | 可逆ゲル化組成物および使用方法 | |
US5686094A (en) | Controlled release formulations for the treatment of xerostomia | |
KR100218654B1 (ko) | 조직 보습 조성물 및 방법 | |
JP2694166B2 (ja) | ゲル形成液体担体組成物 | |
US5110605A (en) | Calcium polycarbophil-alginate controlled release composition and method | |
US5599534A (en) | Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use | |
JP7339725B2 (ja) | 水溶性超分子複合体 | |
AU669351B2 (en) | Method of the treatment of dry nose syndrome | |
EP1499359B1 (fr) | Systemes d'administration thermosensibles | |
Bruschi et al. | Mucoadhesive and mucus-penetrating polymers for drug delivery | |
EP0497956B1 (fr) | Formulations de liberation controlee | |
WO1998029487A1 (fr) | Reticulats polymeres sensibles et leurs procedes d'utilisation | |
JP5979466B2 (ja) | 粘性液組成物 | |
Mfoafo et al. | Thiolated polymers: An overview of mucoadhesive properties and their potential in drug delivery via mucosal tissues | |
EP0429156A1 (fr) | Procédé d'hydratation de tissus et composition | |
EP3222270A1 (fr) | Compositions pour une adhérence aux muqueuses et leurs utilisations | |
JP2002516617A (ja) | 反応性ポリマー網状構造体及びその使用法 | |
CN112741801A (zh) | 一种新型卡波非聚合物及其给药系统 |